How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Restore Protections for Dialysis Patients Act
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 2199/S. 1173, Restore Protections for Dialysis Patients Act H.R. 6214, Kidney Care Access Protection Act S. 2730, Kidney Care Access Protection Act Implementation of P.L. 118-14, Continuing Appropriations Act, 2024 and Other Extensions Act, including provisions related to Title III, Health and Human Services. Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance. FY 2026 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Implementation of P.L. 118-158, the American Relief Act of 2025, including provisions relating to health care.
Restore Protections for Dialysis Patients Act
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
AKEBIA THERAPEUTICS, INC. via AKEBIA THERAPEUTICS, INC.
2026 · second_quarter · Q2
H.R. 2199/S. 1173, Restore Protections for Dialysis Patients Act H.R. 6214, Kidney Care Access Protection Act S. 2730, Kidney Care Access Protection Act Implementation of P.L. 118-14, Continuing Appropriations Act, 2024 and Other Extensions Act, including provisions related to Title III, Health and Human Services. Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance. FY 2026 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Implementation of P.L. 118-158, the American Relief Act of 2025, including provisions relating to health care.
Source: Senate LDA
H.R. 2199/S. 1173, Restore Protections for Dialysis Patients Act H.R. 6214, Kidney Care Access Protection Act S. 2730, Kidney Care Access Protection Act Implementation of P.L. 118-14, Continuing Appropriations Act, 2024 and Other Extensions Act, including provisions related to Title III, Health and Human Services. Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance. FY 2026 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Implementation of P.L. 118-158, the American Relief Act of 2025, including provisions relating to health care.
Kidney Care Access Protection Act
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 2199/S. 1173, Restore Protections for Dialysis Patients Act H.R. 6214, Kidney Care Access Protection Act S. 2730, Kidney Care Access Protection Act Implementation of P.L. 118-14, Continuing Appropriations Act, 2024 and Other Extensions Act, including provisions related to Title III, Health and Human Services. Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance. FY 2026 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Implementation of P.L. 118-158, the American Relief Act of 2025, including provisions relating to health care.
Kidney Care Access Protection Act
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 2199/S. 1173, Restore Protections for Dialysis Patients Act H.R. 6214, Kidney Care Access Protection Act S. 2730, Kidney Care Access Protection Act Implementation of P.L. 118-14, Continuing Appropriations Act, 2024 and Other Extensions Act, including provisions related to Title III, Health and Human Services. Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance. FY 2026 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Implementation of P.L. 118-158, the American Relief Act of 2025, including provisions relating to health care.
Restore Protections for Dialysis Patients Act
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 2199/S. 1173, Restore Protections for Dialysis Patients Act H.R. 6214, Kidney Care Access Protection Act S. 2730, Kidney Care Access Protection Act Implementation of P.L. 118-14, Continuing Appropriations Act, 2024 and Other Extensions Act, including provisions related to Title III, Health and Human Services. Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance. FY 2026 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Implementation of P.L. 118-158, the American Relief Act of 2025, including provisions relating to health care.
Restore Protections for Dialysis Patients Act
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 2199/S. 1173, Restore Protections for Dialysis Patients Act H.R. 6214, Kidney Care Access Protection Act S. 2730, Kidney Care Access Protection Act Implementation of P.L. 118-14, Continuing Appropriations Act, 2024 and Other Extensions Act, including provisions related to Title III, Health and Human Services. Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance. FY 2026 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Implementation of P.L. 118-158, the American Relief Act of 2025, including provisions relating to health care.
Kidney Care Access Protection Act
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 2199/S. 1173, Restore Protections for Dialysis Patients Act H.R. 6214, Kidney Care Access Protection Act S. 2730, Kidney Care Access Protection Act Implementation of P.L. 118-14, Continuing Appropriations Act, 2024 and Other Extensions Act, including provisions related to Title III, Health and Human Services. Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance. FY 2026 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Implementation of P.L. 118-158, the American Relief Act of 2025, including provisions relating to health care.
Kidney Care Access Protection Act
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 2199/S. 1173, Restore Protections for Dialysis Patients Act H.R. 6214, Kidney Care Access Protection Act S. 2730, Kidney Care Access Protection Act Implementation of P.L. 118-14, Continuing Appropriations Act, 2024 and Other Extensions Act, including provisions related to Title III, Health and Human Services. Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance. FY 2026 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Implementation of P.L. 118-158, the American Relief Act of 2025, including provisions relating to health care.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 1, One Big Beautiful Bill Act, provisions related to health care H.R. 2199/S. 1173, Restore Protections for Dialysis Patients Act Implementation of P.L. 118-14, Continuing Appropriations Act, 2024 and Other Extensions Act, including provisions related to Title III, Health and Human Services. Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance. FY 2025 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Implementation of P.L. 118-158, the American Relief Act of 2025, including provisions relating to health care.
Restore Protections for Dialysis Patients Act
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 1, One Big Beautiful Bill Act, provisions related to health care H.R. 2199/S. 1173, Restore Protections for Dialysis Patients Act Implementation of P.L. 118-14, Continuing Appropriations Act, 2024 and Other Extensions Act, including provisions related to Title III, Health and Human Services. Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance. FY 2025 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Implementation of P.L. 118-158, the American Relief Act of 2025, including provisions relating to health care.
Restore Protections for Dialysis Patients Act
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 2199/S. 1173, Restore Protections for Dialysis Patients Act S. 2730, Kidney Care Access Protection Act Implementation of P.L. 118-14, Continuing Appropriations Act, 2024 and Other Extensions Act, including provisions related to Title III, Health and Human Services. Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance. FY 2026 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Implementation of P.L. 118-158, the American Relief Act of 2025, including provisions relating to health care.
Restore Protections for Dialysis Patients Act
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 2199/S. 1173, Restore Protections for Dialysis Patients Act H.R. 6214, Kidney Care Access Protection Act S. 2730, Kidney Care Access Protection Act Implementation of P.L. 118-14, Continuing Appropriations Act, 2024 and Other Extensions Act, including provisions related to Title III, Health and Human Services. Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance. FY 2026 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Implementation of P.L. 118-158, the American Relief Act of 2025, including provisions relating to health care.
Restore Protections for Dialysis Patients Act
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 2199/S. 1173, Restore Protections for Dialysis Patients Act Implementation of P.L. 118-14, Continuing Appropriations Act, 2024 and Other Extensions Act, including provisions related to Title III, Health and Human Services. Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance. FY 2025 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Implementation of P.L. 118-158, the American Relief Act of 2025, including provisions relating to health care.
Kidney Care Access Protection Act
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 2199/S. 1173, Restore Protections for Dialysis Patients Act H.R. 6214, Kidney Care Access Protection Act S. 2730, Kidney Care Access Protection Act Implementation of P.L. 118-14, Continuing Appropriations Act, 2024 and Other Extensions Act, including provisions related to Title III, Health and Human Services. Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance. FY 2026 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Implementation of P.L. 118-158, the American Relief Act of 2025, including provisions relating to health care.
Restore Protections for Dialysis Patients Act
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 2199/S. 1173, Restore Protections for Dialysis Patients Act H.R. 6214, Kidney Care Access Protection Act S. 2730, Kidney Care Access Protection Act Implementation of P.L. 118-14, Continuing Appropriations Act, 2024 and Other Extensions Act, including provisions related to Title III, Health and Human Services. Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance. FY 2026 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Implementation of P.L. 118-158, the American Relief Act of 2025, including provisions relating to health care.
Restore Protections for Dialysis Patients Act
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 2199/S. 1173, Restore Protections for Dialysis Patients Act S. 2730, Kidney Care Access Protection Act Implementation of P.L. 118-14, Continuing Appropriations Act, 2024 and Other Extensions Act, including provisions related to Title III, Health and Human Services. Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance. FY 2026 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Implementation of P.L. 118-158, the American Relief Act of 2025, including provisions relating to health care.
Restore Protections for Dialysis Patients Act
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 2199/S. 1173, Restore Protections for Dialysis Patients Act Implementation of P.L. 118-14, Continuing Appropriations Act, 2024 and Other Extensions Act, including provisions related to Title III, Health and Human Services. Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance. FY 2025 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Implementation of P.L. 118-158, the American Relief Act of 2025, including provisions relating to health care.
Restore Protections for Dialysis Patients Act
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 1, One Big Beautiful Bill Act, provisions related to health care H.R. 2199/S. 1173, Restore Protections for Dialysis Patients Act Implementation of P.L. 118-14, Continuing Appropriations Act, 2024 and Other Extensions Act, including provisions related to Title III, Health and Human Services. Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance. FY 2025 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Implementation of P.L. 118-158, the American Relief Act of 2025, including provisions relating to health care.
Kidney Care Access Protection Act
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 2199/S. 1173, Restore Protections for Dialysis Patients Act H.R. 6214, Kidney Care Access Protection Act S. 2730, Kidney Care Access Protection Act Implementation of P.L. 118-14, Continuing Appropriations Act, 2024 and Other Extensions Act, including provisions related to Title III, Health and Human Services. Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance. FY 2026 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Implementation of P.L. 118-158, the American Relief Act of 2025, including provisions relating to health care.
Kidney Care Access Protection Act
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 2199/S. 1173, Restore Protections for Dialysis Patients Act S. 2730, Kidney Care Access Protection Act Implementation of P.L. 118-14, Continuing Appropriations Act, 2024 and Other Extensions Act, including provisions related to Title III, Health and Human Services. Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance. FY 2026 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Implementation of P.L. 118-158, the American Relief Act of 2025, including provisions relating to health care.
Consolidated Appropriations Act, 2024
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 4366, Consolidated Appropriations Act of 2024, including provisions relating to health care H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023 H.R. 6860, Restore Protections for Dialysis Patients Act H.R. 7085, BIOSECURE Act S. 3558, to prohibit contracting with certain biotechnology providers, and for other purposes Implementation of P.L. 118-14, Continuing Appropriations Act, 2024 and Other Extensions Act, including provisions related to Title III, Health and Human Services. Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance FY 2025 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Consolidated Appropriations Act, 2024
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 4366, Consolidated Appropriations Act of 2024, including provisions relating to health care H.R. 5027, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023 H.R. 6860, Restore Protections for Dialysis Patients Act H.R. 7085, BIOSECURE Act S. 3558, to prohibit contracting with certain biotechnology providers, and for other purposes Implementation of P.L. 118-14, Continuing Appropriations Act, 2024 and Other Extensions Act, including provisions related to Title III, Health and Human Services. Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance CY 2024 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Consolidated Appropriations Act, 2024
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 4366, Consolidated Appropriations Act of 2024, including provisions relating to health care H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023 H.R. 6860, Restore Protections for Dialysis Patients Act H.R. 7085, BIOSECURE Act S. 3558, to prohibit contracting with certain biotechnology providers, and for other purposes Implementation of P.L. 118-14, Continuing Appropriations Act, 2024 and Other Extensions Act, including provisions related to Title III, Health and Human Services. Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance FY 2025 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Implementation of P.L. 118-158, the American Relief Act of 2025, including provisions relating to health care
Consolidated Appropriations Act, 2024
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 4366, Consolidated Appropriations Act of 2024, including provisions relating to health care H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023 H.R. 6860, Restore Protections for Dialysis Patients Act H.R. 7085, BIOSECURE Act S. 3558, to prohibit contracting with certain biotechnology providers, and for other purposes Implementation of P.L. 118-14, Continuing Appropriations Act, 2024 and Other Extensions Act, including provisions related to Title III, Health and Human Services. Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance FY 2025 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Kidney Disease Improvement in Research and Treatment Act of 2023
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 4366, Consolidated Appropriations Act of 2024, including provisions relating to health care H.R. 5027, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023 H.R. 6860, Restore Protections for Dialysis Patients Act H.R. 7085, BIOSECURE Act S. 3558, to prohibit contracting with certain biotechnology providers, and for other purposes Implementation of P.L. 118-14, Continuing Appropriations Act, 2024 and Other Extensions Act, including provisions related to Title III, Health and Human Services. Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance CY 2024 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Kidney Disease Improvement in Research and Treatment Act of 2023
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 4366, Consolidated Appropriations Act of 2024, including provisions relating to health care H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023 H.R. 6860, Restore Protections for Dialysis Patients Act H.R. 7085, BIOSECURE Act S. 3558, to prohibit contracting with certain biotechnology providers, and for other purposes Implementation of P.L. 118-14, Continuing Appropriations Act, 2024 and Other Extensions Act, including provisions related to Title III, Health and Human Services. Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance FY 2025 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Implementation of P.L. 118-158, the American Relief Act of 2025, including provisions relating to health care
Chronic Kidney Disease Improvement in Research and Treatment Act of 2023
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 4366, Consolidated Appropriations Act of 2024, including provisions relating to health care H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023 H.R. 6860, Restore Protections for Dialysis Patients Act H.R. 7085, BIOSECURE Act S. 3558, to prohibit contracting with certain biotechnology providers, and for other purposes Implementation of P.L. 118-14, Continuing Appropriations Act, 2024 and Other Extensions Act, including provisions related to Title III, Health and Human Services. Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance FY 2025 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Kidney Disease Improvement in Research and Treatment Act of 2023
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 4366, Consolidated Appropriations Act of 2024, including provisions relating to health care H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023 H.R. 6860, Restore Protections for Dialysis Patients Act H.R. 7085, BIOSECURE Act S. 3558, to prohibit contracting with certain biotechnology providers, and for other purposes Implementation of P.L. 118-14, Continuing Appropriations Act, 2024 and Other Extensions Act, including provisions related to Title III, Health and Human Services. Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance FY 2025 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Kidney PATIENT Act of 2023
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
HR 5074/S. 4510, Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments (PATIENT) Act of 2023 Implementation of the Inflation Reduction Act of 2022, P.L. 117-169, drug pricing provisions Policy and technical issues related to the Medicare Advantage program and Medicare Part D prescription drug program Center for Medicare and Medicaid Innovation (CMMI) mandatory and voluntary demonstration programs for patients with chronic kidney disease Implementation of Executive Order 13879, Advancing American Kidney Health CMS proposed inclusion of phosphate binders in the End Stage Renal Disease (ESRD) Prospective Payment System (PPS) Implementation of the 21st Century Cures Act of 2016, P.L. 114-255, extension of Medicare Advantage to Medicare ESRD patients Proposed CY 2025 End Stage Renal Disease (ESRD) Prospective Payment System (PPS), Payment for Renal Dialysis Services Furnished to Individuals with Acute Kidney Injury (AKI), End Stage Renal Disease Quality Improvement Program (QIP), and End Stage Renal Disease Treatment Choices Model (ETC)
Kidney PATIENT Act of 2023
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
HR 5074/S. 4510, Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments (PATIENT) Act of 2023 Implementation of the Inflation Reduction Act of 2022, P.L. 117-169, drug pricing provisions Policy and technical issues related to the Medicare Advantage program and Medicare Part D prescription drug program Center for Medicare and Medicaid Innovation (CMMI) mandatory and voluntary demonstration programs for patients with chronic kidney disease Implementation of Executive Order 13879, Advancing American Kidney Health CMS proposed inclusion of phosphate binders in the End Stage Renal Disease (ESRD) Prospective Payment System (PPS) Implementation of the 21st Century Cures Act of 2016, P.L. 114-255, extension of Medicare Advantage to Medicare ESRD patients Proposed CY 2025 End Stage Renal Disease (ESRD) Prospective Payment System (PPS), Payment for Renal Dialysis Services Furnished to Individuals with Acute Kidney Injury (AKI), End Stage Renal Disease Quality Improvement Program (QIP), and End Stage Renal Disease Treatment Choices Model (ETC)
Kidney PATIENT Act of 2023
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
HR 5074/S. 4510, Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments (PATIENT) Act of 2023 Implementation of the Inflation Reduction Act of 2022, P.L. 117-169, drug pricing provisions Policy and technical issues related to the Medicare Advantage program and Medicare Part D prescription drug program Center for Medicare and Medicaid Innovation (CMMI) mandatory and voluntary demonstration programs for patients with chronic kidney disease Implementation of Executive Order 13879, Advancing American Kidney Health CMS proposed inclusion of phosphate binders in the End Stage Renal Disease (ESRD) Prospective Payment System (PPS) Implementation of the 21st Century Cures Act of 2016, P.L. 114-255, extension of Medicare Advantage to Medicare ESRD patients Proposed CY 2025 End Stage Renal Disease (ESRD) Prospective Payment System (PPS), Payment for Renal Dialysis Services Furnished to Individuals with Acute Kidney Injury (AKI), End Stage Renal Disease Quality Improvement Program (QIP), and End Stage Renal Disease Treatment Choices Model (ETC)
Kidney PATIENT Act of 2023
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
HR 5074, Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments (PATIENT) Act of 2023 Implementation of the Inflation Reduction Act of 2022, P.L. 117-169, drug pricing provisions Quality Improvement Program (QIP) in the End Stage Renal Disease (ESRD) prospective payment system (PPS) Implementation of Final CY 2024 End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and Quality Improvement Program (QIP) Rule Policy and technical issues related to the Medicare Advantage program and Medicare Part D prescription drug program Center for Medicare and Medicaid Innovation (CMMI) mandatory and voluntary demonstration programs for patients with chronic kidney disease Implementation of Executive Order 13879, Advancing American Kidney Health CMS proposed inclusion of phosphate binders in the End Stage Renal Disease (ESRD) Prospective Payment System (PPS) Implementation of the 21st Century Cures Act of 2016, P.L. 114-255, extension of Medicare Advantage to Medicare ESRD patients
Restore Protections for Dialysis Patients Act
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 4366, Consolidated Appropriations Act of 2024, including provisions relating to health care H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023 H.R. 6860, Restore Protections for Dialysis Patients Act H.R. 7085, BIOSECURE Act S. 3558, to prohibit contracting with certain biotechnology providers, and for other purposes Implementation of P.L. 118-14, Continuing Appropriations Act, 2024 and Other Extensions Act, including provisions related to Title III, Health and Human Services. Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance FY 2025 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Implementation of P.L. 118-158, the American Relief Act of 2025, including provisions relating to health care
Restore Protections for Dialysis Patients Act
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 4366, Consolidated Appropriations Act of 2024, including provisions relating to health care H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023 H.R. 6860, Restore Protections for Dialysis Patients Act H.R. 7085, BIOSECURE Act S. 3558, to prohibit contracting with certain biotechnology providers, and for other purposes Implementation of P.L. 118-14, Continuing Appropriations Act, 2024 and Other Extensions Act, including provisions related to Title III, Health and Human Services. Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance FY 2025 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Restore Protections for Dialysis Patients Act
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 4366, Consolidated Appropriations Act of 2024, including provisions relating to health care H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023 H.R. 6860, Restore Protections for Dialysis Patients Act H.R. 7085, BIOSECURE Act S. 3558, to prohibit contracting with certain biotechnology providers, and for other purposes Implementation of P.L. 118-14, Continuing Appropriations Act, 2024 and Other Extensions Act, including provisions related to Title III, Health and Human Services. Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance FY 2025 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Restore Protections for Dialysis Patients Act
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 4366, Consolidated Appropriations Act of 2024, including provisions relating to health care H.R. 5027, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023 H.R. 6860, Restore Protections for Dialysis Patients Act H.R. 7085, BIOSECURE Act S. 3558, to prohibit contracting with certain biotechnology providers, and for other purposes Implementation of P.L. 118-14, Continuing Appropriations Act, 2024 and Other Extensions Act, including provisions related to Title III, Health and Human Services. Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance CY 2024 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
H.R. 4366, Consolidated Appropriations Act of 2024, including provisions relating to health care H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023 H.R. 6860, Restore Protections for Dialysis Patients Act H.R. 7085, BIOSECURE Act S. 3558, to prohibit contracting with certain biotechnology providers, and for other purposes Implementation of P.L. 118-14, Continuing Appropriations Act, 2024 and Other Extensions Act, including provisions related to Title III, Health and Human Services. Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance FY 2025 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Implementation of P.L. 118-158, the American Relief Act of 2025, including provisions relating to health care
H.R. 4366, Consolidated Appropriations Act of 2024, including provisions relating to health care H.R. 5027, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023 H.R. 6860, Restore Protections for Dialysis Patients Act H.R. 7085, BIOSECURE Act S. 3558, to prohibit contracting with certain biotechnology providers, and for other purposes Implementation of P.L. 118-14, Continuing Appropriations Act, 2024 and Other Extensions Act, including provisions related to Title III, Health and Human Services. Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance CY 2024 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
H.R. 4366, Consolidated Appropriations Act of 2024, including provisions relating to health care H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023 H.R. 6860, Restore Protections for Dialysis Patients Act H.R. 7085, BIOSECURE Act S. 3558, to prohibit contracting with certain biotechnology providers, and for other purposes Implementation of P.L. 118-14, Continuing Appropriations Act, 2024 and Other Extensions Act, including provisions related to Title III, Health and Human Services. Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance FY 2025 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
H.R. 4366, Consolidated Appropriations Act of 2024, including provisions relating to health care H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023 H.R. 6860, Restore Protections for Dialysis Patients Act H.R. 7085, BIOSECURE Act S. 3558, to prohibit contracting with certain biotechnology providers, and for other purposes Implementation of P.L. 118-14, Continuing Appropriations Act, 2024 and Other Extensions Act, including provisions related to Title III, Health and Human Services. Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance FY 2025 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Prohibiting Foreign Access to American Genetic Information Act of 2024
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 4366, Consolidated Appropriations Act of 2024, including provisions relating to health care H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023 H.R. 6860, Restore Protections for Dialysis Patients Act H.R. 7085, BIOSECURE Act S. 3558, to prohibit contracting with certain biotechnology providers, and for other purposes Implementation of P.L. 118-14, Continuing Appropriations Act, 2024 and Other Extensions Act, including provisions related to Title III, Health and Human Services. Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance FY 2025 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Prohibiting Foreign Access to American Genetic Information Act of 2024
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 4366, Consolidated Appropriations Act of 2024, including provisions relating to health care H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023 H.R. 6860, Restore Protections for Dialysis Patients Act H.R. 7085, BIOSECURE Act S. 3558, to prohibit contracting with certain biotechnology providers, and for other purposes Implementation of P.L. 118-14, Continuing Appropriations Act, 2024 and Other Extensions Act, including provisions related to Title III, Health and Human Services. Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance FY 2025 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Prohibiting Foreign Access to American Genetic Information Act of 2024
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 4366, Consolidated Appropriations Act of 2024, including provisions relating to health care H.R. 5027, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023 H.R. 6860, Restore Protections for Dialysis Patients Act H.R. 7085, BIOSECURE Act S. 3558, to prohibit contracting with certain biotechnology providers, and for other purposes Implementation of P.L. 118-14, Continuing Appropriations Act, 2024 and Other Extensions Act, including provisions related to Title III, Health and Human Services. Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance CY 2024 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Prohibiting Foreign Access to American Genetic Information Act of 2024
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 4366, Consolidated Appropriations Act of 2024, including provisions relating to health care H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023 H.R. 6860, Restore Protections for Dialysis Patients Act H.R. 7085, BIOSECURE Act S. 3558, to prohibit contracting with certain biotechnology providers, and for other purposes Implementation of P.L. 118-14, Continuing Appropriations Act, 2024 and Other Extensions Act, including provisions related to Title III, Health and Human Services. Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance FY 2025 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Implementation of P.L. 118-158, the American Relief Act of 2025, including provisions relating to health care
Chronic Kidney Disease Improvement in Research and Treatment Act of 2024
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 4366, Consolidated Appropriations Act of 2024, including provisions relating to health care H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023 H.R. 6860, Restore Protections for Dialysis Patients Act H.R. 7085, BIOSECURE Act S. 3558, to prohibit contracting with certain biotechnology providers, and for other purposes Implementation of P.L. 118-14, Continuing Appropriations Act, 2024 and Other Extensions Act, including provisions related to Title III, Health and Human Services. Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance FY 2025 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Kidney Disease Improvement in Research and Treatment Act of 2024
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 4366, Consolidated Appropriations Act of 2024, including provisions relating to health care H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023 H.R. 6860, Restore Protections for Dialysis Patients Act H.R. 7085, BIOSECURE Act S. 3558, to prohibit contracting with certain biotechnology providers, and for other purposes Implementation of P.L. 118-14, Continuing Appropriations Act, 2024 and Other Extensions Act, including provisions related to Title III, Health and Human Services. Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance FY 2025 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Kidney Disease Improvement in Research and Treatment Act of 2024
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 4366, Consolidated Appropriations Act of 2024, including provisions relating to health care H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023 H.R. 6860, Restore Protections for Dialysis Patients Act H.R. 7085, BIOSECURE Act S. 3558, to prohibit contracting with certain biotechnology providers, and for other purposes Implementation of P.L. 118-14, Continuing Appropriations Act, 2024 and Other Extensions Act, including provisions related to Title III, Health and Human Services. Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance FY 2025 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Implementation of P.L. 118-158, the American Relief Act of 2025, including provisions relating to health care
Kidney PATIENT Act of 2024
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
HR 5074/S. 4510, Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments (PATIENT) Act of 2023 Implementation of the Inflation Reduction Act of 2022, P.L. 117-169, drug pricing provisions Policy and technical issues related to the Medicare Advantage program and Medicare Part D prescription drug program Center for Medicare and Medicaid Innovation (CMMI) mandatory and voluntary demonstration programs for patients with chronic kidney disease Implementation of Executive Order 13879, Advancing American Kidney Health CMS proposed inclusion of phosphate binders in the End Stage Renal Disease (ESRD) Prospective Payment System (PPS) Implementation of the 21st Century Cures Act of 2016, P.L. 114-255, extension of Medicare Advantage to Medicare ESRD patients Proposed CY 2025 End Stage Renal Disease (ESRD) Prospective Payment System (PPS), Payment for Renal Dialysis Services Furnished to Individuals with Acute Kidney Injury (AKI), End Stage Renal Disease Quality Improvement Program (QIP), and End Stage Renal Disease Treatment Choices Model (ETC)
Kidney PATIENT Act of 2024
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
HR 5074/S. 4510, Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments (PATIENT) Act of 2023 Implementation of the Inflation Reduction Act of 2022, P.L. 117-169, drug pricing provisions Policy and technical issues related to the Medicare Advantage program and Medicare Part D prescription drug program Center for Medicare and Medicaid Innovation (CMMI) mandatory and voluntary demonstration programs for patients with chronic kidney disease Implementation of Executive Order 13879, Advancing American Kidney Health CMS proposed inclusion of phosphate binders in the End Stage Renal Disease (ESRD) Prospective Payment System (PPS) Implementation of the 21st Century Cures Act of 2016, P.L. 114-255, extension of Medicare Advantage to Medicare ESRD patients Proposed CY 2025 End Stage Renal Disease (ESRD) Prospective Payment System (PPS), Payment for Renal Dialysis Services Furnished to Individuals with Acute Kidney Injury (AKI), End Stage Renal Disease Quality Improvement Program (QIP), and End Stage Renal Disease Treatment Choices Model (ETC)
Kidney PATIENT Act of 2024
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
HR 5074/S. 4510, Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments (PATIENT) Act of 2023 Implementation of the Inflation Reduction Act of 2022, P.L. 117-169, drug pricing provisions Policy and technical issues related to the Medicare Advantage program and Medicare Part D prescription drug program Center for Medicare and Medicaid Innovation (CMMI) mandatory and voluntary demonstration programs for patients with chronic kidney disease Implementation of Executive Order 13879, Advancing American Kidney Health CMS proposed inclusion of phosphate binders in the End Stage Renal Disease (ESRD) Prospective Payment System (PPS) Implementation of the 21st Century Cures Act of 2016, P.L. 114-255, extension of Medicare Advantage to Medicare ESRD patients Proposed CY 2025 End Stage Renal Disease (ESRD) Prospective Payment System (PPS), Payment for Renal Dialysis Services Furnished to Individuals with Acute Kidney Injury (AKI), End Stage Renal Disease Quality Improvement Program (QIP), and End Stage Renal Disease Treatment Choices Model (ETC)
Securing the U.S. Organ Procurement and Transplantation Network Act
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 2544/S. 1668, Securing the U.S. Organ Procurement and Transplantation Network Act HR 5027, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023 Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance CY 2024 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Kidney Disease Improvement in Research and Treatment Act of 2023
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 2544/S. 1668, Securing the U.S. Organ Procurement and Transplantation Network Act HR 5027, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023 Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance CY 2024 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Kidney PATIENT Act of 2023
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
HR 5074, Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments (PATIENT) Act of 2023 Implementation of the Inflation Reduction Act of 2022, P.L. 117-169, drug pricing provisions Quality Improvement Program (QIP) in the End Stage Renal Disease (ESRD) prospective payment system (PPS) Implementation of Final CY 2024 End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and Quality Improvement Program (QIP) Rule Policy and technical issues related to the Medicare Advantage program and Medicare Part D prescription drug program Center for Medicare and Medicaid Innovation (CMMI) mandatory and voluntary demonstration programs for patients with chronic kidney disease Implementation of Executive Order 13879, Advancing American Kidney Health CMS proposed inclusion of phosphate binders in the End Stage Renal Disease (ESRD) Prospective Payment System (PPS) Implementation of the 21st Century Cures Act of 2016, P.L. 114-255, extension of Medicare Advantage to Medicare ESRD patients
Kidney PATIENT Act of 2023
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
HR 5074, Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments (PATIENT) Act of 2023 Implementation of the Inflation Reduction Act of 2022, P.L. 117-169, drug pricing provisions Quality Improvement Program (QIP) in the End Stage Renal Disease (ESRD) prospective payment system (PPS) Proposed CY 2024 End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and Quality Improvement Program (QIP) rule Policy and technical issues related to the Medicare Advantage program and Medicare Part D prescription drug program Center for Medicare and Medicaid Innovation (CMMI) mandatory and voluntary demonstration programs for patients with chronic kidney disease Implementation of Executive Order 13879, Advancing American Kidney Health CMS proposed inclusion of phosphate binders in the End Stage Renal Disease (ESRD) Prospective Payment System (PPS) Implementation of the 21st Century Cures Act of 2016, P.L. 114-255, extension of Medicare Advantage to Medicare ESRD patients
Securing the U.S. Organ Procurement and Transplantation Network Act
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 2544/S. 1668, Securing the U.S. Organ Procurement and Transplantation Network Act HR 5027, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023 Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance CY 2024 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Living Donor Protection Act of 2021
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 1255/S. 377, The Living Donor Protection Act of 2021 H.R. 2617, Consolidated Appropriations Act, 2023, issues related to health care H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 5376, Build Back Better Act, provisions relating to health care H.R. 5585, Advanced Research Project Agency Health Act H.R. 6000, Cures 2.0 Act S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 Implementation of Executive Order 13879, Advancing American Kidney Health.
Living Donor Protection Act of 2021
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 1255/S. 377, The Living Donor Protection Act of 2021 H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 5376, Build Back Better Act, provisions relating to health care H.R. 5585, Advanced Research Project Agency Health Act H.R. 6000, Cures 2.0 Act S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 Implementation of Executive Order 13879, Advancing American Kidney Health.
Living Donor Protection Act of 2021
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 1255/S. 377, The Living Donor Protection Act of 2021 H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 5376, Build Back Better Act, provisions relating to health care H.R. 5585, Advanced Research Project Agency Health Act H.R. 6000, Cures 2.0 Act S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 Implementation of Executive Order 13879, Advancing American Kidney Health.
Living Donor Protection Act of 2021
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 1255/S. 377, The Living Donor Protection Act of 2021 H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 5376, Build Back Better Act, provisions relating to health care H.R. 5585, Advanced Research Project Agency Health Act H.R. 6000, Cures 2.0 Act S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 Implementation of Executive Order 13879, Advancing American Kidney Health.
Jack Reynolds Memory Medigap Expansion Act
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 2934, Renal Anemia Innovation Support and Expansion (RAISE) Act S. 4011, Capping Drug Costs for Seniors Act of 2022 H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 4417, Capping Drug Costs for Seniors Act of 2021 H.R. 5260, Reduced Costs and Continued Cures Act H.R. 6973, Enhanced Access to Affordable Medicines Act of 2022 H.R. 7634, Protecting Health Care for All Patients Act of 2022 S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 S. 2317, Seniors Prescription Drug Relief Act Issues related to Medicare Part D coverage for drugs indicated to treat patients with chronic kidney disease; Quality Improvement Program (QIP) in the End Stage Renal Disease (ESRD) prospective payment system; CY 2022 Medicare End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and Quality Improvement Program (QIP) rule making; CY 2022 policy and technical issues changes to the Medicare Advantage Program and Medicare Prescription Drug Benefit Program; Centers for Medicare and Medicaid Innovation (CMMI) ESRD Treatment Choices (ETC) model; Implementation of expanded Medicare immunosuppressive drug coverage for kidney transplant patients; Implementation of Executive Order 13879, Advancing American Kidney Health; Telehealth flexibilities for nephrologists and kidney patients on dialysis.
Jack Reynolds Memory Medigap Expansion Act
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 1255/S. 377, The Living Donor Protection Act of 2021 H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 5376, Build Back Better Act, provisions relating to health care H.R. 5585, Advanced Research Project Agency Health Act H.R. 6000, Cures 2.0 Act S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 Implementation of Executive Order 13879, Advancing American Kidney Health.
Jack Reynolds Memory Medigap Expansion Act
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 2934, Renal Anemia Innovation Support and Expansion (RAISE) Act S. 4011, Capping Drug Costs for Seniors Act of 2022 H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 4417, Capping Drug Costs for Seniors Act of 2021 H.R. 5260, Reduced Costs and Continued Cures Act H.R. 6973, Enhanced Access to Affordable Medicines Act of 2022 H.R. 7634, Protecting Health Care for All Patients Act of 2022 S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 S. 2317, Seniors Prescription Drug Relief Act Issues related to Medicare Part D coverage for drugs indicated to treat patients with chronic kidney disease; Quality Improvement Program (QIP) in the End Stage Renal Disease (ESRD) prospective payment system; CY 2022 Medicare End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and Quality Improvement Program (QIP) rule making; CY 2022 policy and technical issues changes to the Medicare Advantage Program and Medicare Prescription Drug Benefit Program; Centers for Medicare and Medicaid Innovation (CMMI) ESRD Treatment Choices (ETC) model; Implementation of expanded Medicare immunosuppressive drug coverage for kidney transplant patients; Implementation of Executive Order 13879, Advancing American Kidney Health; Telehealth flexibilities for nephrologists and kidney patients on dialysis.
Jack Reynolds Memory Medigap Expansion Act
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 1255/S. 377, The Living Donor Protection Act of 2021 H.R. 2617, Consolidated Appropriations Act, 2023, issues related to health care H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 5376, Build Back Better Act, provisions relating to health care H.R. 5585, Advanced Research Project Agency Health Act H.R. 6000, Cures 2.0 Act S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 Implementation of Executive Order 13879, Advancing American Kidney Health.
Jack Reynolds Memory Medigap Expansion Act
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 2934, Renal Anemia Innovation Support and Expansion (RAISE) Act S. 4011, Capping Drug Costs for Seniors Act of 2022 H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 4417, Capping Drug Costs for Seniors Act of 2021 H.R. 5260, Reduced Costs and Continued Cures Act H.R. 6973, Enhanced Access to Affordable Medicines Act of 2022 H.R. 7634, Protecting Health Care for All Patients Act of 2022 S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 S. 2317, Seniors Prescription Drug Relief Act Issues related to Medicare Part D coverage for drugs indicated to treat patients with chronic kidney disease; Quality Improvement Program (QIP) in the End Stage Renal Disease (ESRD) prospective payment system; CY 2022 Medicare End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and Quality Improvement Program (QIP) rule making; CY 2022 policy and technical issues changes to the Medicare Advantage Program and Medicare Prescription Drug Benefit Program; Centers for Medicare and Medicaid Innovation (CMMI) ESRD Treatment Choices (ETC) model; Implementation of expanded Medicare immunosuppressive drug coverage for kidney transplant patients; Implementation of Executive Order 13879, Advancing American Kidney Health; Telehealth flexibilities for nephrologists and kidney patients on dialysis.
Jack Reynolds Memory Medigap Expansion Act
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 2934, Renal Anemia Innovation Support and Expansion (RAISE) Act S. 4011, Capping Drug Costs for Seniors Act of 2022 H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 4417, Capping Drug Costs for Seniors Act of 2021 H.R. 5260, Reduced Costs and Continued Cures Act S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 S. 2317, Seniors Prescription Drug Relief Act Issues related to Medicare Part D coverage for drugs indicated to treat patients with chronic kidney disease; Quality Improvement Program (QIP) in the End Stage Renal Disease (ESRD) prospective payment system; CY 2022 Medicare End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and Quality Improvement Program (QIP) rule making; CY 2022 policy and technical issues changes to the Medicare Advantage Program and Medicare Prescription Drug Benefit Program; Centers for Medicare and Medicaid Innovation (CMMI) ESRD Treatment Choices (ETC) model; Implementation of expanded Medicare immunosuppressive drug coverage for kidney transplant patients; Implementation of Executive Order 13879, Advancing American Kidney Health; Telehealth flexibilities for nephrologists and kidney patients on dialysis.
Jack Reynolds Memory Medigap Expansion Act
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 1255/S. 377, The Living Donor Protection Act of 2021 H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 5376, Build Back Better Act, provisions relating to health care H.R. 5585, Advanced Research Project Agency Health Act H.R. 6000, Cures 2.0 Act S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 Implementation of Executive Order 13879, Advancing American Kidney Health.
Jack Reynolds Memory Medigap Expansion Act
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 1255/S. 377, The Living Donor Protection Act of 2021 H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 5376, Build Back Better Act, provisions relating to health care H.R. 5585, Advanced Research Project Agency Health Act H.R. 6000, Cures 2.0 Act S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 Implementation of Executive Order 13879, Advancing American Kidney Health.
Consolidated Appropriations Act, 2023
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 1255/S. 377, The Living Donor Protection Act of 2021 H.R. 2617, Consolidated Appropriations Act, 2023, issues related to health care H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 5376, Build Back Better Act, provisions relating to health care H.R. 5585, Advanced Research Project Agency Health Act H.R. 6000, Cures 2.0 Act S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 Implementation of Executive Order 13879, Advancing American Kidney Health.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 2934, Renal Anemia Innovation Support and Expansion (RAISE) Act S. 4011, Capping Drug Costs for Seniors Act of 2022 H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 4417, Capping Drug Costs for Seniors Act of 2021 H.R. 5260, Reduced Costs and Continued Cures Act H.R. 6973, Enhanced Access to Affordable Medicines Act of 2022 H.R. 7634, Protecting Health Care for All Patients Act of 2022 S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 S. 2317, Seniors Prescription Drug Relief Act Issues related to Medicare Part D coverage for drugs indicated to treat patients with chronic kidney disease; Quality Improvement Program (QIP) in the End Stage Renal Disease (ESRD) prospective payment system; CY 2022 Medicare End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and Quality Improvement Program (QIP) rule making; CY 2022 policy and technical issues changes to the Medicare Advantage Program and Medicare Prescription Drug Benefit Program; Centers for Medicare and Medicaid Innovation (CMMI) ESRD Treatment Choices (ETC) model; Implementation of expanded Medicare immunosuppressive drug coverage for kidney transplant patients; Implementation of Executive Order 13879, Advancing American Kidney Health; Telehealth flexibilities for nephrologists and kidney patients on dialysis.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 2934, Renal Anemia Innovation Support and Expansion (RAISE) Act S. 4011, Capping Drug Costs for Seniors Act of 2022 H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 4417, Capping Drug Costs for Seniors Act of 2021 H.R. 5260, Reduced Costs and Continued Cures Act H.R. 6973, Enhanced Access to Affordable Medicines Act of 2022 H.R. 7634, Protecting Health Care for All Patients Act of 2022 S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 S. 2317, Seniors Prescription Drug Relief Act Issues related to Medicare Part D coverage for drugs indicated to treat patients with chronic kidney disease; Quality Improvement Program (QIP) in the End Stage Renal Disease (ESRD) prospective payment system; CY 2022 Medicare End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and Quality Improvement Program (QIP) rule making; CY 2022 policy and technical issues changes to the Medicare Advantage Program and Medicare Prescription Drug Benefit Program; Centers for Medicare and Medicaid Innovation (CMMI) ESRD Treatment Choices (ETC) model; Implementation of expanded Medicare immunosuppressive drug coverage for kidney transplant patients; Implementation of Executive Order 13879, Advancing American Kidney Health; Telehealth flexibilities for nephrologists and kidney patients on dialysis.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 2934, Renal Anemia Innovation Support and Expansion (RAISE) Act S. 4011, Capping Drug Costs for Seniors Act of 2022 H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 4417, Capping Drug Costs for Seniors Act of 2021 H.R. 5260, Reduced Costs and Continued Cures Act H.R. 6973, Enhanced Access to Affordable Medicines Act of 2022 H.R. 7634, Protecting Health Care for All Patients Act of 2022 S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 S. 2317, Seniors Prescription Drug Relief Act Issues related to Medicare Part D coverage for drugs indicated to treat patients with chronic kidney disease; Quality Improvement Program (QIP) in the End Stage Renal Disease (ESRD) prospective payment system; CY 2022 Medicare End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and Quality Improvement Program (QIP) rule making; CY 2022 policy and technical issues changes to the Medicare Advantage Program and Medicare Prescription Drug Benefit Program; Centers for Medicare and Medicaid Innovation (CMMI) ESRD Treatment Choices (ETC) model; Implementation of expanded Medicare immunosuppressive drug coverage for kidney transplant patients; Implementation of Executive Order 13879, Advancing American Kidney Health; Telehealth flexibilities for nephrologists and kidney patients on dialysis.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 2934, Renal Anemia Innovation Support and Expansion (RAISE) Act S. 4011, Capping Drug Costs for Seniors Act of 2022 H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 4417, Capping Drug Costs for Seniors Act of 2021 H.R. 5260, Reduced Costs and Continued Cures Act S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 S. 2317, Seniors Prescription Drug Relief Act Issues related to Medicare Part D coverage for drugs indicated to treat patients with chronic kidney disease; Quality Improvement Program (QIP) in the End Stage Renal Disease (ESRD) prospective payment system; CY 2022 Medicare End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and Quality Improvement Program (QIP) rule making; CY 2022 policy and technical issues changes to the Medicare Advantage Program and Medicare Prescription Drug Benefit Program; Centers for Medicare and Medicaid Innovation (CMMI) ESRD Treatment Choices (ETC) model; Implementation of expanded Medicare immunosuppressive drug coverage for kidney transplant patients; Implementation of Executive Order 13879, Advancing American Kidney Health; Telehealth flexibilities for nephrologists and kidney patients on dialysis.
Elijah E. Cummings Lower Drug Costs Now Act
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 1255/S. 377, The Living Donor Protection Act of 2021 H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 5376, Build Back Better Act, provisions relating to health care H.R. 5585, Advanced Research Project Agency Health Act H.R. 6000, Cures 2.0 Act S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 Implementation of Executive Order 13879, Advancing American Kidney Health.
Elijah E. Cummings Lower Drug Costs Now Act
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 2934, Renal Anemia Innovation Support and Expansion (RAISE) Act S. 4011, Capping Drug Costs for Seniors Act of 2022 H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 4417, Capping Drug Costs for Seniors Act of 2021 H.R. 5260, Reduced Costs and Continued Cures Act H.R. 6973, Enhanced Access to Affordable Medicines Act of 2022 H.R. 7634, Protecting Health Care for All Patients Act of 2022 S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 S. 2317, Seniors Prescription Drug Relief Act Issues related to Medicare Part D coverage for drugs indicated to treat patients with chronic kidney disease; Quality Improvement Program (QIP) in the End Stage Renal Disease (ESRD) prospective payment system; CY 2022 Medicare End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and Quality Improvement Program (QIP) rule making; CY 2022 policy and technical issues changes to the Medicare Advantage Program and Medicare Prescription Drug Benefit Program; Centers for Medicare and Medicaid Innovation (CMMI) ESRD Treatment Choices (ETC) model; Implementation of expanded Medicare immunosuppressive drug coverage for kidney transplant patients; Implementation of Executive Order 13879, Advancing American Kidney Health; Telehealth flexibilities for nephrologists and kidney patients on dialysis.
Elijah E. Cummings Lower Drug Costs Now Act
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 1255/S. 377, The Living Donor Protection Act of 2021 H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 5376, Build Back Better Act, provisions relating to health care H.R. 5585, Advanced Research Project Agency Health Act H.R. 6000, Cures 2.0 Act S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 Implementation of Executive Order 13879, Advancing American Kidney Health.
Elijah E. Cummings Lower Drug Costs Now Act
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 2934, Renal Anemia Innovation Support and Expansion (RAISE) Act S. 4011, Capping Drug Costs for Seniors Act of 2022 H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 4417, Capping Drug Costs for Seniors Act of 2021 H.R. 5260, Reduced Costs and Continued Cures Act H.R. 6973, Enhanced Access to Affordable Medicines Act of 2022 H.R. 7634, Protecting Health Care for All Patients Act of 2022 S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 S. 2317, Seniors Prescription Drug Relief Act Issues related to Medicare Part D coverage for drugs indicated to treat patients with chronic kidney disease; Quality Improvement Program (QIP) in the End Stage Renal Disease (ESRD) prospective payment system; CY 2022 Medicare End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and Quality Improvement Program (QIP) rule making; CY 2022 policy and technical issues changes to the Medicare Advantage Program and Medicare Prescription Drug Benefit Program; Centers for Medicare and Medicaid Innovation (CMMI) ESRD Treatment Choices (ETC) model; Implementation of expanded Medicare immunosuppressive drug coverage for kidney transplant patients; Implementation of Executive Order 13879, Advancing American Kidney Health; Telehealth flexibilities for nephrologists and kidney patients on dialysis.
Elijah E. Cummings Lower Drug Costs Now Act
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 1255/S. 377, The Living Donor Protection Act of 2021 H.R. 2617, Consolidated Appropriations Act, 2023, issues related to health care H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 5376, Build Back Better Act, provisions relating to health care H.R. 5585, Advanced Research Project Agency Health Act H.R. 6000, Cures 2.0 Act S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 Implementation of Executive Order 13879, Advancing American Kidney Health.
Elijah E. Cummings Lower Drug Costs Now Act
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 2934, Renal Anemia Innovation Support and Expansion (RAISE) Act S. 4011, Capping Drug Costs for Seniors Act of 2022 H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 4417, Capping Drug Costs for Seniors Act of 2021 H.R. 5260, Reduced Costs and Continued Cures Act H.R. 6973, Enhanced Access to Affordable Medicines Act of 2022 H.R. 7634, Protecting Health Care for All Patients Act of 2022 S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 S. 2317, Seniors Prescription Drug Relief Act Issues related to Medicare Part D coverage for drugs indicated to treat patients with chronic kidney disease; Quality Improvement Program (QIP) in the End Stage Renal Disease (ESRD) prospective payment system; CY 2022 Medicare End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and Quality Improvement Program (QIP) rule making; CY 2022 policy and technical issues changes to the Medicare Advantage Program and Medicare Prescription Drug Benefit Program; Centers for Medicare and Medicaid Innovation (CMMI) ESRD Treatment Choices (ETC) model; Implementation of expanded Medicare immunosuppressive drug coverage for kidney transplant patients; Implementation of Executive Order 13879, Advancing American Kidney Health; Telehealth flexibilities for nephrologists and kidney patients on dialysis.
Elijah E. Cummings Lower Drug Costs Now Act
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 2934, Renal Anemia Innovation Support and Expansion (RAISE) Act S. 4011, Capping Drug Costs for Seniors Act of 2022 H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 4417, Capping Drug Costs for Seniors Act of 2021 H.R. 5260, Reduced Costs and Continued Cures Act S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 S. 2317, Seniors Prescription Drug Relief Act Issues related to Medicare Part D coverage for drugs indicated to treat patients with chronic kidney disease; Quality Improvement Program (QIP) in the End Stage Renal Disease (ESRD) prospective payment system; CY 2022 Medicare End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and Quality Improvement Program (QIP) rule making; CY 2022 policy and technical issues changes to the Medicare Advantage Program and Medicare Prescription Drug Benefit Program; Centers for Medicare and Medicaid Innovation (CMMI) ESRD Treatment Choices (ETC) model; Implementation of expanded Medicare immunosuppressive drug coverage for kidney transplant patients; Implementation of Executive Order 13879, Advancing American Kidney Health; Telehealth flexibilities for nephrologists and kidney patients on dialysis.
Elijah E. Cummings Lower Drug Costs Now Act
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 1255/S. 377, The Living Donor Protection Act of 2021 H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 5376, Build Back Better Act, provisions relating to health care H.R. 5585, Advanced Research Project Agency Health Act H.R. 6000, Cures 2.0 Act S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 Implementation of Executive Order 13879, Advancing American Kidney Health.
Chronic Kidney Disease Improvement in Research and Treatment Act of 2021
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 1255/S. 377, The Living Donor Protection Act of 2021 H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 5376, Build Back Better Act, provisions relating to health care H.R. 5585, Advanced Research Project Agency Health Act H.R. 6000, Cures 2.0 Act S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 Implementation of Executive Order 13879, Advancing American Kidney Health.
Chronic Kidney Disease Improvement in Research and Treatment Act of 2021
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 2934, Renal Anemia Innovation Support and Expansion (RAISE) Act S. 4011, Capping Drug Costs for Seniors Act of 2022 H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 4417, Capping Drug Costs for Seniors Act of 2021 H.R. 5260, Reduced Costs and Continued Cures Act H.R. 6973, Enhanced Access to Affordable Medicines Act of 2022 H.R. 7634, Protecting Health Care for All Patients Act of 2022 S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 S. 2317, Seniors Prescription Drug Relief Act Issues related to Medicare Part D coverage for drugs indicated to treat patients with chronic kidney disease; Quality Improvement Program (QIP) in the End Stage Renal Disease (ESRD) prospective payment system; CY 2022 Medicare End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and Quality Improvement Program (QIP) rule making; CY 2022 policy and technical issues changes to the Medicare Advantage Program and Medicare Prescription Drug Benefit Program; Centers for Medicare and Medicaid Innovation (CMMI) ESRD Treatment Choices (ETC) model; Implementation of expanded Medicare immunosuppressive drug coverage for kidney transplant patients; Implementation of Executive Order 13879, Advancing American Kidney Health; Telehealth flexibilities for nephrologists and kidney patients on dialysis.
Chronic Kidney Disease Improvement in Research and Treatment Act of 2021
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 1255/S. 377, The Living Donor Protection Act of 2021 H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 5376, Build Back Better Act, provisions relating to health care H.R. 5585, Advanced Research Project Agency Health Act H.R. 6000, Cures 2.0 Act S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 Implementation of Executive Order 13879, Advancing American Kidney Health.
Chronic Kidney Disease Improvement in Research and Treatment Act of 2021
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 2934, Renal Anemia Innovation Support and Expansion (RAISE) Act S. 4011, Capping Drug Costs for Seniors Act of 2022 H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 4417, Capping Drug Costs for Seniors Act of 2021 H.R. 5260, Reduced Costs and Continued Cures Act H.R. 6973, Enhanced Access to Affordable Medicines Act of 2022 H.R. 7634, Protecting Health Care for All Patients Act of 2022 S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 S. 2317, Seniors Prescription Drug Relief Act Issues related to Medicare Part D coverage for drugs indicated to treat patients with chronic kidney disease; Quality Improvement Program (QIP) in the End Stage Renal Disease (ESRD) prospective payment system; CY 2022 Medicare End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and Quality Improvement Program (QIP) rule making; CY 2022 policy and technical issues changes to the Medicare Advantage Program and Medicare Prescription Drug Benefit Program; Centers for Medicare and Medicaid Innovation (CMMI) ESRD Treatment Choices (ETC) model; Implementation of expanded Medicare immunosuppressive drug coverage for kidney transplant patients; Implementation of Executive Order 13879, Advancing American Kidney Health; Telehealth flexibilities for nephrologists and kidney patients on dialysis.
Chronic Kidney Disease Improvement in Research and Treatment Act of 2021
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 1255/S. 377, The Living Donor Protection Act of 2021 H.R. 2617, Consolidated Appropriations Act, 2023, issues related to health care H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 5376, Build Back Better Act, provisions relating to health care H.R. 5585, Advanced Research Project Agency Health Act H.R. 6000, Cures 2.0 Act S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 Implementation of Executive Order 13879, Advancing American Kidney Health.
Chronic Kidney Disease Improvement in Research and Treatment Act of 2021
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 2934, Renal Anemia Innovation Support and Expansion (RAISE) Act S. 4011, Capping Drug Costs for Seniors Act of 2022 H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 4417, Capping Drug Costs for Seniors Act of 2021 H.R. 5260, Reduced Costs and Continued Cures Act H.R. 6973, Enhanced Access to Affordable Medicines Act of 2022 H.R. 7634, Protecting Health Care for All Patients Act of 2022 S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 S. 2317, Seniors Prescription Drug Relief Act Issues related to Medicare Part D coverage for drugs indicated to treat patients with chronic kidney disease; Quality Improvement Program (QIP) in the End Stage Renal Disease (ESRD) prospective payment system; CY 2022 Medicare End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and Quality Improvement Program (QIP) rule making; CY 2022 policy and technical issues changes to the Medicare Advantage Program and Medicare Prescription Drug Benefit Program; Centers for Medicare and Medicaid Innovation (CMMI) ESRD Treatment Choices (ETC) model; Implementation of expanded Medicare immunosuppressive drug coverage for kidney transplant patients; Implementation of Executive Order 13879, Advancing American Kidney Health; Telehealth flexibilities for nephrologists and kidney patients on dialysis.
Chronic Kidney Disease Improvement in Research and Treatment Act of 2021
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 2934, Renal Anemia Innovation Support and Expansion (RAISE) Act S. 4011, Capping Drug Costs for Seniors Act of 2022 H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 4417, Capping Drug Costs for Seniors Act of 2021 H.R. 5260, Reduced Costs and Continued Cures Act S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 S. 2317, Seniors Prescription Drug Relief Act Issues related to Medicare Part D coverage for drugs indicated to treat patients with chronic kidney disease; Quality Improvement Program (QIP) in the End Stage Renal Disease (ESRD) prospective payment system; CY 2022 Medicare End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and Quality Improvement Program (QIP) rule making; CY 2022 policy and technical issues changes to the Medicare Advantage Program and Medicare Prescription Drug Benefit Program; Centers for Medicare and Medicaid Innovation (CMMI) ESRD Treatment Choices (ETC) model; Implementation of expanded Medicare immunosuppressive drug coverage for kidney transplant patients; Implementation of Executive Order 13879, Advancing American Kidney Health; Telehealth flexibilities for nephrologists and kidney patients on dialysis.
Chronic Kidney Disease Improvement in Research and Treatment Act of 2021
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 1255/S. 377, The Living Donor Protection Act of 2021 H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 5376, Build Back Better Act, provisions relating to health care H.R. 5585, Advanced Research Project Agency Health Act H.R. 6000, Cures 2.0 Act S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 Implementation of Executive Order 13879, Advancing American Kidney Health.
Capping Drug Costs for Seniors Act of 2021
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 2934, Renal Anemia Innovation Support and Expansion (RAISE) Act S. 4011, Capping Drug Costs for Seniors Act of 2022 H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 4417, Capping Drug Costs for Seniors Act of 2021 H.R. 5260, Reduced Costs and Continued Cures Act H.R. 6973, Enhanced Access to Affordable Medicines Act of 2022 H.R. 7634, Protecting Health Care for All Patients Act of 2022 S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 S. 2317, Seniors Prescription Drug Relief Act Issues related to Medicare Part D coverage for drugs indicated to treat patients with chronic kidney disease; Quality Improvement Program (QIP) in the End Stage Renal Disease (ESRD) prospective payment system; CY 2022 Medicare End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and Quality Improvement Program (QIP) rule making; CY 2022 policy and technical issues changes to the Medicare Advantage Program and Medicare Prescription Drug Benefit Program; Centers for Medicare and Medicaid Innovation (CMMI) ESRD Treatment Choices (ETC) model; Implementation of expanded Medicare immunosuppressive drug coverage for kidney transplant patients; Implementation of Executive Order 13879, Advancing American Kidney Health; Telehealth flexibilities for nephrologists and kidney patients on dialysis.
Capping Drug Costs for Seniors Act of 2021
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 2934, Renal Anemia Innovation Support and Expansion (RAISE) Act S. 4011, Capping Drug Costs for Seniors Act of 2022 H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 4417, Capping Drug Costs for Seniors Act of 2021 H.R. 5260, Reduced Costs and Continued Cures Act S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 S. 2317, Seniors Prescription Drug Relief Act Issues related to Medicare Part D coverage for drugs indicated to treat patients with chronic kidney disease; Quality Improvement Program (QIP) in the End Stage Renal Disease (ESRD) prospective payment system; CY 2022 Medicare End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and Quality Improvement Program (QIP) rule making; CY 2022 policy and technical issues changes to the Medicare Advantage Program and Medicare Prescription Drug Benefit Program; Centers for Medicare and Medicaid Innovation (CMMI) ESRD Treatment Choices (ETC) model; Implementation of expanded Medicare immunosuppressive drug coverage for kidney transplant patients; Implementation of Executive Order 13879, Advancing American Kidney Health; Telehealth flexibilities for nephrologists and kidney patients on dialysis.
Capping Drug Costs for Seniors Act of 2021
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 2934, Renal Anemia Innovation Support and Expansion (RAISE) Act S. 4011, Capping Drug Costs for Seniors Act of 2022 H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 4417, Capping Drug Costs for Seniors Act of 2021 H.R. 5260, Reduced Costs and Continued Cures Act H.R. 6973, Enhanced Access to Affordable Medicines Act of 2022 H.R. 7634, Protecting Health Care for All Patients Act of 2022 S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 S. 2317, Seniors Prescription Drug Relief Act Issues related to Medicare Part D coverage for drugs indicated to treat patients with chronic kidney disease; Quality Improvement Program (QIP) in the End Stage Renal Disease (ESRD) prospective payment system; CY 2022 Medicare End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and Quality Improvement Program (QIP) rule making; CY 2022 policy and technical issues changes to the Medicare Advantage Program and Medicare Prescription Drug Benefit Program; Centers for Medicare and Medicaid Innovation (CMMI) ESRD Treatment Choices (ETC) model; Implementation of expanded Medicare immunosuppressive drug coverage for kidney transplant patients; Implementation of Executive Order 13879, Advancing American Kidney Health; Telehealth flexibilities for nephrologists and kidney patients on dialysis.
Capping Drug Costs for Seniors Act of 2021
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 2934, Renal Anemia Innovation Support and Expansion (RAISE) Act S. 4011, Capping Drug Costs for Seniors Act of 2022 H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 4417, Capping Drug Costs for Seniors Act of 2021 H.R. 5260, Reduced Costs and Continued Cures Act H.R. 6973, Enhanced Access to Affordable Medicines Act of 2022 H.R. 7634, Protecting Health Care for All Patients Act of 2022 S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 S. 2317, Seniors Prescription Drug Relief Act Issues related to Medicare Part D coverage for drugs indicated to treat patients with chronic kidney disease; Quality Improvement Program (QIP) in the End Stage Renal Disease (ESRD) prospective payment system; CY 2022 Medicare End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and Quality Improvement Program (QIP) rule making; CY 2022 policy and technical issues changes to the Medicare Advantage Program and Medicare Prescription Drug Benefit Program; Centers for Medicare and Medicaid Innovation (CMMI) ESRD Treatment Choices (ETC) model; Implementation of expanded Medicare immunosuppressive drug coverage for kidney transplant patients; Implementation of Executive Order 13879, Advancing American Kidney Health; Telehealth flexibilities for nephrologists and kidney patients on dialysis.
Reduced Costs and Continued Cures Act
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 2934, Renal Anemia Innovation Support and Expansion (RAISE) Act S. 4011, Capping Drug Costs for Seniors Act of 2022 H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 4417, Capping Drug Costs for Seniors Act of 2021 H.R. 5260, Reduced Costs and Continued Cures Act H.R. 6973, Enhanced Access to Affordable Medicines Act of 2022 H.R. 7634, Protecting Health Care for All Patients Act of 2022 S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 S. 2317, Seniors Prescription Drug Relief Act Issues related to Medicare Part D coverage for drugs indicated to treat patients with chronic kidney disease; Quality Improvement Program (QIP) in the End Stage Renal Disease (ESRD) prospective payment system; CY 2022 Medicare End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and Quality Improvement Program (QIP) rule making; CY 2022 policy and technical issues changes to the Medicare Advantage Program and Medicare Prescription Drug Benefit Program; Centers for Medicare and Medicaid Innovation (CMMI) ESRD Treatment Choices (ETC) model; Implementation of expanded Medicare immunosuppressive drug coverage for kidney transplant patients; Implementation of Executive Order 13879, Advancing American Kidney Health; Telehealth flexibilities for nephrologists and kidney patients on dialysis.
Reduced Costs and Continued Cures Act
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 2934, Renal Anemia Innovation Support and Expansion (RAISE) Act S. 4011, Capping Drug Costs for Seniors Act of 2022 H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 4417, Capping Drug Costs for Seniors Act of 2021 H.R. 5260, Reduced Costs and Continued Cures Act S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 S. 2317, Seniors Prescription Drug Relief Act Issues related to Medicare Part D coverage for drugs indicated to treat patients with chronic kidney disease; Quality Improvement Program (QIP) in the End Stage Renal Disease (ESRD) prospective payment system; CY 2022 Medicare End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and Quality Improvement Program (QIP) rule making; CY 2022 policy and technical issues changes to the Medicare Advantage Program and Medicare Prescription Drug Benefit Program; Centers for Medicare and Medicaid Innovation (CMMI) ESRD Treatment Choices (ETC) model; Implementation of expanded Medicare immunosuppressive drug coverage for kidney transplant patients; Implementation of Executive Order 13879, Advancing American Kidney Health; Telehealth flexibilities for nephrologists and kidney patients on dialysis.
Reduced Costs and Continued Cures Act
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 2934, Renal Anemia Innovation Support and Expansion (RAISE) Act S. 4011, Capping Drug Costs for Seniors Act of 2022 H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 4417, Capping Drug Costs for Seniors Act of 2021 H.R. 5260, Reduced Costs and Continued Cures Act H.R. 6973, Enhanced Access to Affordable Medicines Act of 2022 H.R. 7634, Protecting Health Care for All Patients Act of 2022 S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 S. 2317, Seniors Prescription Drug Relief Act Issues related to Medicare Part D coverage for drugs indicated to treat patients with chronic kidney disease; Quality Improvement Program (QIP) in the End Stage Renal Disease (ESRD) prospective payment system; CY 2022 Medicare End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and Quality Improvement Program (QIP) rule making; CY 2022 policy and technical issues changes to the Medicare Advantage Program and Medicare Prescription Drug Benefit Program; Centers for Medicare and Medicaid Innovation (CMMI) ESRD Treatment Choices (ETC) model; Implementation of expanded Medicare immunosuppressive drug coverage for kidney transplant patients; Implementation of Executive Order 13879, Advancing American Kidney Health; Telehealth flexibilities for nephrologists and kidney patients on dialysis.
Reduced Costs and Continued Cures Act
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 2934, Renal Anemia Innovation Support and Expansion (RAISE) Act S. 4011, Capping Drug Costs for Seniors Act of 2022 H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 4417, Capping Drug Costs for Seniors Act of 2021 H.R. 5260, Reduced Costs and Continued Cures Act H.R. 6973, Enhanced Access to Affordable Medicines Act of 2022 H.R. 7634, Protecting Health Care for All Patients Act of 2022 S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 S. 2317, Seniors Prescription Drug Relief Act Issues related to Medicare Part D coverage for drugs indicated to treat patients with chronic kidney disease; Quality Improvement Program (QIP) in the End Stage Renal Disease (ESRD) prospective payment system; CY 2022 Medicare End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and Quality Improvement Program (QIP) rule making; CY 2022 policy and technical issues changes to the Medicare Advantage Program and Medicare Prescription Drug Benefit Program; Centers for Medicare and Medicaid Innovation (CMMI) ESRD Treatment Choices (ETC) model; Implementation of expanded Medicare immunosuppressive drug coverage for kidney transplant patients; Implementation of Executive Order 13879, Advancing American Kidney Health; Telehealth flexibilities for nephrologists and kidney patients on dialysis.
Inflation Reduction Act of 2022
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 1255/S. 377, The Living Donor Protection Act of 2021 H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 5376, Build Back Better Act, provisions relating to health care H.R. 5585, Advanced Research Project Agency Health Act H.R. 6000, Cures 2.0 Act S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 Implementation of Executive Order 13879, Advancing American Kidney Health.
Inflation Reduction Act of 2022
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 1255/S. 377, The Living Donor Protection Act of 2021 H.R. 2617, Consolidated Appropriations Act, 2023, issues related to health care H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 5376, Build Back Better Act, provisions relating to health care H.R. 5585, Advanced Research Project Agency Health Act H.R. 6000, Cures 2.0 Act S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 Implementation of Executive Order 13879, Advancing American Kidney Health.
Inflation Reduction Act of 2022
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 1255/S. 377, The Living Donor Protection Act of 2021 H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 5376, Build Back Better Act, provisions relating to health care H.R. 5585, Advanced Research Project Agency Health Act H.R. 6000, Cures 2.0 Act S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 Implementation of Executive Order 13879, Advancing American Kidney Health.
Inflation Reduction Act of 2022
Client: AKEBIA THERAPEUTICS, INC. · Firm: AKEBIA THERAPEUTICS, INC.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 1255/S. 377, The Living Donor Protection Act of 2021 H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 5376, Build Back Better Act, provisions relating to health care H.R. 5585, Advanced Research Project Agency Health Act H.R. 6000, Cures 2.0 Act S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 Implementation of Executive Order 13879, Advancing American Kidney Health.
Implementation of the Inflation Reduction Act of 2022, P.L. 117-169, drug pricing provisions. Policy and technical issues related to the Medicare Advantage program and Medicare Part D prescription drug program. Center for Medicare and Medicaid Innovation (CMMI) mandatory and voluntary demonstration programs for patients with chronic kidney disease. CMSs inclusion of phosphate binders in the End Stage Renal Disease (ESRD) Prospective Payment System (PPS). Implementation of the 21st Century Cures Act of 2016, P.L. 114-255, extension of Medicare Advantage to Medicare ESRD patients. Final CY 2026 End Stage Renal Disease (ESRD) Prospective Payment System (PPS), Payment for Renal Dialysis Services Furnished to Individuals with Acute Kidney Injury (AKI), End Stage Renal Disease Quality Improvement Program (QIP), and End Stage Renal Disease Treatment Choices Model (ETC).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
AKEBIA THERAPEUTICS, INC. via AKEBIA THERAPEUTICS, INC.
2026 · first_quarter · Q1
Implementation of the Inflation Reduction Act of 2022, P.L. 117-169, drug pricing provisions. Policy and technical issues related to the Medicare Advantage program and Medicare Part D prescription drug program. Center for Medicare and Medicaid Innovation (CMMI) mandatory and voluntary demonstration programs for patients with chronic kidney disease. CMSs inclusion of phosphate binders in the End Stage Renal Disease (ESRD) Prospective Payment System (PPS). Implementation of the 21st Century Cures Act of 2016, P.L. 114-255, extension of Medicare Advantage to Medicare ESRD patients. Final CY 2026 End Stage Renal Disease (ESRD) Prospective Payment System (PPS), Payment for Renal Dialysis Services Furnished to Individuals with Acute Kidney Injury (AKI), End Stage Renal Disease Quality Improvement Program (QIP), and End Stage Renal Disease Treatment Choices Model (ETC).
H.R. 2199/S. 1173, Restore Protections for Dialysis Patients Act H.R. 6214, Kidney Care Access Protection Act S. 2730, Kidney Care Access Protection Act Implementation of P.L. 118-14, Continuing Appropriations Act, 2024 and Other Extensions Act, including provisions related to Title III, Health and Human Services. Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance. FY 2026 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Implementation of P.L. 118-158, the American Relief Act of 2025, including provisions relating to health care.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
AKEBIA THERAPEUTICS, INC. via AKEBIA THERAPEUTICS, INC.
2025 · fourth_quarter · Q4
H.R. 2199/S. 1173, Restore Protections for Dialysis Patients Act H.R. 6214, Kidney Care Access Protection Act S. 2730, Kidney Care Access Protection Act Implementation of P.L. 118-14, Continuing Appropriations Act, 2024 and Other Extensions Act, including provisions related to Title III, Health and Human Services. Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance. FY 2026 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Implementation of P.L. 118-158, the American Relief Act of 2025, including provisions relating to health care.
Implementation of the Inflation Reduction Act of 2022, P.L. 117-169, drug pricing provisions. Policy and technical issues related to the Medicare Advantage program and Medicare Part D prescription drug program. Center for Medicare and Medicaid Innovation (CMMI) mandatory and voluntary demonstration programs for patients with chronic kidney disease. CMSs inclusion of phosphate binders in the End Stage Renal Disease (ESRD) Prospective Payment System (PPS). Implementation of the 21st Century Cures Act of 2016, P.L. 114-255, extension of Medicare Advantage to Medicare ESRD patients. Proposed CY 2026 End Stage Renal Disease (ESRD) Prospective Payment System (PPS), Payment for Renal Dialysis Services Furnished to Individuals with Acute Kidney Injury (AKI), End Stage Renal Disease Quality Improvement Program (QIP), and End Stage Renal Disease Treatment Choices Model (ETC).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AKEBIA THERAPEUTICS, INC. via AKEBIA THERAPEUTICS, INC.
2025 · third_quarter · Q3
H.R. 2199/S. 1173, Restore Protections for Dialysis Patients Act S. 2730, Kidney Care Access Protection Act Implementation of P.L. 118-14, Continuing Appropriations Act, 2024 and Other Extensions Act, including provisions related to Title III, Health and Human Services. Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance. FY 2026 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Implementation of P.L. 118-158, the American Relief Act of 2025, including provisions relating to health care.
Implementation of the Inflation Reduction Act of 2022, P.L. 117-169, drug pricing provisions. Policy and technical issues related to the Medicare Advantage program and Medicare Part D prescription drug program. Center for Medicare and Medicaid Innovation (CMMI) mandatory and voluntary demonstration programs for patients with chronic kidney disease. CMSs inclusion of phosphate binders in the End Stage Renal Disease (ESRD) Prospective Payment System (PPS). Implementation of the 21st Century Cures Act of 2016, P.L. 114-255, extension of Medicare Advantage to Medicare ESRD patients. Proposed CY 2026 End Stage Renal Disease (ESRD) Prospective Payment System (PPS), Payment for Renal Dialysis Services Furnished to Individuals with Acute Kidney Injury (AKI), End Stage Renal Disease Quality Improvement Program (QIP), and End Stage Renal Disease Treatment Choices Model (ETC).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AKEBIA THERAPEUTICS, INC. via AKEBIA THERAPEUTICS, INC.
2025 · second_quarter · Q2
H.R. 1, One Big Beautiful Bill Act, provisions related to health care H.R. 2199/S. 1173, Restore Protections for Dialysis Patients Act Implementation of P.L. 118-14, Continuing Appropriations Act, 2024 and Other Extensions Act, including provisions related to Title III, Health and Human Services. Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance. FY 2025 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Implementation of P.L. 118-158, the American Relief Act of 2025, including provisions relating to health care.
Implementation of the Inflation Reduction Act of 2022, P.L. 117-169, drug pricing provisions. Policy and technical issues related to the Medicare Advantage program and Medicare Part D prescription drug program. Center for Medicare and Medicaid Innovation (CMMI) mandatory and voluntary demonstration programs for patients with chronic kidney disease. CMSs inclusion of phosphate binders in the End Stage Renal Disease (ESRD) Prospective Payment System (PPS). Implementation of the 21st Century Cures Act of 2016, P.L. 114-255, extension of Medicare Advantage to Medicare ESRD patients. Implementation of the final CY 2025 End Stage Renal Disease (ESRD) Prospective Payment System (PPS), Payment for Renal Dialysis Services Furnished to Individuals with Acute Kidney Injury (AKI), End Stage Renal Disease Quality Improvement Program (QIP), and End Stage Renal Disease Treatment Choices Model (ETC).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AKEBIA THERAPEUTICS, INC. via AKEBIA THERAPEUTICS, INC.
2025 · first_quarter · Q1
H.R. 2199/S. 1173, Restore Protections for Dialysis Patients Act Implementation of P.L. 118-14, Continuing Appropriations Act, 2024 and Other Extensions Act, including provisions related to Title III, Health and Human Services. Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance. FY 2025 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Implementation of P.L. 118-158, the American Relief Act of 2025, including provisions relating to health care.
Implementation of the Inflation Reduction Act of 2022, P.L. 117-169, drug pricing provisions. Policy and technical issues related to the Medicare Advantage program and Medicare Part D prescription drug program. Center for Medicare and Medicaid Innovation (CMMI) mandatory and voluntary demonstration programs for patients with chronic kidney disease. CMSs inclusion of phosphate binders in the End Stage Renal Disease (ESRD) Prospective Payment System (PPS). Implementation of the 21st Century Cures Act of 2016, P.L. 114-255, extension of Medicare Advantage to Medicare ESRD patients. Implementation of the final CY 2025 End Stage Renal Disease (ESRD) Prospective Payment System (PPS), Payment for Renal Dialysis Services Furnished to Individuals with Acute Kidney Injury (AKI), End Stage Renal Disease Quality Improvement Program (QIP), and End Stage Renal Disease Treatment Choices Model (ETC).
AKEBIA THERAPEUTICS, INC. via AKEBIA THERAPEUTICS, INC.
2024 · fourth_quarter · Q4
H.R. 4366, Consolidated Appropriations Act of 2024, including provisions relating to health care H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023 H.R. 6860, Restore Protections for Dialysis Patients Act H.R. 7085, BIOSECURE Act S. 3558, to prohibit contracting with certain biotechnology providers, and for other purposes Implementation of P.L. 118-14, Continuing Appropriations Act, 2024 and Other Extensions Act, including provisions related to Title III, Health and Human Services. Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance FY 2025 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Implementation of P.L. 118-158, the American Relief Act of 2025, including provisions relating to health care
HR 5074/S. 4510, Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments (PATIENT) Act of 2023 Implementation of the Inflation Reduction Act of 2022, P.L. 117-169, drug pricing provisions Policy and technical issues related to the Medicare Advantage program and Medicare Part D prescription drug program Center for Medicare and Medicaid Innovation (CMMI) mandatory and voluntary demonstration programs for patients with chronic kidney disease Implementation of Executive Order 13879, Advancing American Kidney Health CMS proposed inclusion of phosphate binders in the End Stage Renal Disease (ESRD) Prospective Payment System (PPS) Implementation of the 21st Century Cures Act of 2016, P.L. 114-255, extension of Medicare Advantage to Medicare ESRD patients Proposed CY 2025 End Stage Renal Disease (ESRD) Prospective Payment System (PPS), Payment for Renal Dialysis Services Furnished to Individuals with Acute Kidney Injury (AKI), End Stage Renal Disease Quality Improvement Program (QIP), and End Stage Renal Disease Treatment Choices Model (ETC)
AKEBIA THERAPEUTICS, INC. via AKEBIA THERAPEUTICS, INC.
2024 · third_quarter · Q3
H.R. 4366, Consolidated Appropriations Act of 2024, including provisions relating to health care H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023 H.R. 6860, Restore Protections for Dialysis Patients Act H.R. 7085, BIOSECURE Act S. 3558, to prohibit contracting with certain biotechnology providers, and for other purposes Implementation of P.L. 118-14, Continuing Appropriations Act, 2024 and Other Extensions Act, including provisions related to Title III, Health and Human Services. Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance FY 2025 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
HR 5074/S. 4510, Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments (PATIENT) Act of 2023 Implementation of the Inflation Reduction Act of 2022, P.L. 117-169, drug pricing provisions Policy and technical issues related to the Medicare Advantage program and Medicare Part D prescription drug program Center for Medicare and Medicaid Innovation (CMMI) mandatory and voluntary demonstration programs for patients with chronic kidney disease Implementation of Executive Order 13879, Advancing American Kidney Health CMS proposed inclusion of phosphate binders in the End Stage Renal Disease (ESRD) Prospective Payment System (PPS) Implementation of the 21st Century Cures Act of 2016, P.L. 114-255, extension of Medicare Advantage to Medicare ESRD patients Proposed CY 2025 End Stage Renal Disease (ESRD) Prospective Payment System (PPS), Payment for Renal Dialysis Services Furnished to Individuals with Acute Kidney Injury (AKI), End Stage Renal Disease Quality Improvement Program (QIP), and End Stage Renal Disease Treatment Choices Model (ETC)
AKEBIA THERAPEUTICS, INC. via AKEBIA THERAPEUTICS, INC.
2024 · second_quarter · Q2
H.R. 4366, Consolidated Appropriations Act of 2024, including provisions relating to health care H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023 H.R. 6860, Restore Protections for Dialysis Patients Act H.R. 7085, BIOSECURE Act S. 3558, to prohibit contracting with certain biotechnology providers, and for other purposes Implementation of P.L. 118-14, Continuing Appropriations Act, 2024 and Other Extensions Act, including provisions related to Title III, Health and Human Services. Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance FY 2025 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
HR 5074/S. 4510, Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments (PATIENT) Act of 2023 Implementation of the Inflation Reduction Act of 2022, P.L. 117-169, drug pricing provisions Policy and technical issues related to the Medicare Advantage program and Medicare Part D prescription drug program Center for Medicare and Medicaid Innovation (CMMI) mandatory and voluntary demonstration programs for patients with chronic kidney disease Implementation of Executive Order 13879, Advancing American Kidney Health CMS proposed inclusion of phosphate binders in the End Stage Renal Disease (ESRD) Prospective Payment System (PPS) Implementation of the 21st Century Cures Act of 2016, P.L. 114-255, extension of Medicare Advantage to Medicare ESRD patients Proposed CY 2025 End Stage Renal Disease (ESRD) Prospective Payment System (PPS), Payment for Renal Dialysis Services Furnished to Individuals with Acute Kidney Injury (AKI), End Stage Renal Disease Quality Improvement Program (QIP), and End Stage Renal Disease Treatment Choices Model (ETC)
AKEBIA THERAPEUTICS, INC. via AKEBIA THERAPEUTICS, INC.
2024 · first_quarter · Q1
H.R. 4366, Consolidated Appropriations Act of 2024, including provisions relating to health care H.R. 5027, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023 H.R. 6860, Restore Protections for Dialysis Patients Act H.R. 7085, BIOSECURE Act S. 3558, to prohibit contracting with certain biotechnology providers, and for other purposes Implementation of P.L. 118-14, Continuing Appropriations Act, 2024 and Other Extensions Act, including provisions related to Title III, Health and Human Services. Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance CY 2024 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
HR 5074, Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments (PATIENT) Act of 2023 Implementation of the Inflation Reduction Act of 2022, P.L. 117-169, drug pricing provisions Quality Improvement Program (QIP) in the End Stage Renal Disease (ESRD) prospective payment system (PPS) Implementation of Final CY 2024 End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and Quality Improvement Program (QIP) Rule Policy and technical issues related to the Medicare Advantage program and Medicare Part D prescription drug program Center for Medicare and Medicaid Innovation (CMMI) mandatory and voluntary demonstration programs for patients with chronic kidney disease Implementation of Executive Order 13879, Advancing American Kidney Health CMS proposed inclusion of phosphate binders in the End Stage Renal Disease (ESRD) Prospective Payment System (PPS) Implementation of the 21st Century Cures Act of 2016, P.L. 114-255, extension of Medicare Advantage to Medicare ESRD patients
AKEBIA THERAPEUTICS, INC. via AKEBIA THERAPEUTICS, INC.
2023 · fourth_quarter · Q4
HR 5074, Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments (PATIENT) Act of 2023 Implementation of the Inflation Reduction Act of 2022, P.L. 117-169, drug pricing provisions Quality Improvement Program (QIP) in the End Stage Renal Disease (ESRD) prospective payment system (PPS) Implementation of Final CY 2024 End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and Quality Improvement Program (QIP) Rule Policy and technical issues related to the Medicare Advantage program and Medicare Part D prescription drug program Center for Medicare and Medicaid Innovation (CMMI) mandatory and voluntary demonstration programs for patients with chronic kidney disease Implementation of Executive Order 13879, Advancing American Kidney Health CMS proposed inclusion of phosphate binders in the End Stage Renal Disease (ESRD) Prospective Payment System (PPS) Implementation of the 21st Century Cures Act of 2016, P.L. 114-255, extension of Medicare Advantage to Medicare ESRD patients
Implementation of P.L. 118-14, Continuing Appropriations Act, 2024 and Other Extensions Act, including provisions related to Title III, Health and Human Services. Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance CY 2024 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
AKEBIA THERAPEUTICS, INC. via AKEBIA THERAPEUTICS, INC.
2023 · third_quarter · Q3
H.R. 2544/S. 1668, Securing the U.S. Organ Procurement and Transplantation Network Act HR 5027, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023 Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance CY 2024 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
HR 5074, Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments (PATIENT) Act of 2023 Implementation of the Inflation Reduction Act of 2022, P.L. 117-169, drug pricing provisions Quality Improvement Program (QIP) in the End Stage Renal Disease (ESRD) prospective payment system (PPS) Proposed CY 2024 End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and Quality Improvement Program (QIP) rule Policy and technical issues related to the Medicare Advantage program and Medicare Part D prescription drug program Center for Medicare and Medicaid Innovation (CMMI) mandatory and voluntary demonstration programs for patients with chronic kidney disease Implementation of Executive Order 13879, Advancing American Kidney Health CMS proposed inclusion of phosphate binders in the End Stage Renal Disease (ESRD) Prospective Payment System (PPS) Implementation of the 21st Century Cures Act of 2016, P.L. 114-255, extension of Medicare Advantage to Medicare ESRD patients
AKEBIA THERAPEUTICS, INC. via AKEBIA THERAPEUTICS, INC.
2023 · second_quarter · Q2
Implementation of the Inflation Reduction Act of 2022, P.L. 117-169, drug pricing provisions Quality Improvement Program (QIP) in the End Stage Renal Disease (ESRD) prospective payment system (PPS) Proposed CY 2024 End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and Quality Improvement Program (QIP) rule Policy and technical issues related to the Medicare Advantage program and Medicare Part D prescription drug program Center for Medicare and Medicaid Innovation (CMMI) mandatory and voluntary demonstration programs for patients with chronic kidney disease Implementation of Executive Order 13879, Advancing American Kidney Health CMS proposed inclusion of phosphate binders in the End Stage Renal Disease (ESRD) Prospective Payment System (PPS) Implementation of the 21st Century Cures Act of 2016, P.L. 114-255, extension of Medicare Advantage to Medicare ESRD patients
Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance CY 2024 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
AKEBIA THERAPEUTICS, INC. via AKEBIA THERAPEUTICS, INC.
2023 · first_quarter · Q1
Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance CY 2024 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Implementation of the Inflation Reduction Act of 2022, P.L. 117-169, drug pricing provisions Quality Improvement Program (QIP) in the End Stage Renal Disease (ESRD) prospective payment system (PPS) Issues related to payment in the CY 2024 End Stage Renal Disease (ESRD) Prospective Payment System (PPS) Policy and technical issues related to the Medicare Advantage program and Medicare Part D prescription drug program Center for Medicare and Medicaid Innovation (CMMI) mandatory and voluntary demonstration programs for patients with chronic kidney disease Implementation of Executive Order 13879, Advancing American Kidney Health CMS proposed inclusion of phosphate binders in the End Stage Renal Disease (ESRD) Prospective Payment System (PPS) Implementation of the 21st Century Cures Act of 2016, P.L. 114-255, extension of Medicare Advantage to Medicare ESRD patients
AKEBIA THERAPEUTICS, INC. via AKEBIA THERAPEUTICS, INC.
2022 · fourth_quarter · Q4
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 1255/S. 377, The Living Donor Protection Act of 2021 H.R. 2617, Consolidated Appropriations Act, 2023, issues related to health care H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 5376, Build Back Better Act, provisions relating to health care H.R. 5585, Advanced Research Project Agency Health Act H.R. 6000, Cures 2.0 Act S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 Implementation of Executive Order 13879, Advancing American Kidney Health.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 2934, Renal Anemia Innovation Support and Expansion (RAISE) Act S. 4011, Capping Drug Costs for Seniors Act of 2022 H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 4417, Capping Drug Costs for Seniors Act of 2021 H.R. 5260, Reduced Costs and Continued Cures Act H.R. 6973, Enhanced Access to Affordable Medicines Act of 2022 H.R. 7634, Protecting Health Care for All Patients Act of 2022 S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 S. 2317, Seniors Prescription Drug Relief Act Issues related to Medicare Part D coverage for drugs indicated to treat patients with chronic kidney disease; Quality Improvement Program (QIP) in the End Stage Renal Disease (ESRD) prospective payment system; CY 2022 Medicare End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and Quality Improvement Program (QIP) rule making; CY 2022 policy and technical issues changes to the Medicare Advantage Program and Medicare Prescription Drug Benefit Program; Centers for Medicare and Medicaid Innovation (CMMI) ESRD Treatment Choices (ETC) model; Implementation of expanded Medicare immunosuppressive drug coverage for kidney transplant patients; Implementation of Executive Order 13879, Advancing American Kidney Health; Telehealth flexibilities for nephrologists and kidney patients on dialysis.
AKEBIA THERAPEUTICS, INC. via AKEBIA THERAPEUTICS, INC.
2022 · third_quarter · Q3
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 2934, Renal Anemia Innovation Support and Expansion (RAISE) Act S. 4011, Capping Drug Costs for Seniors Act of 2022 H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 4417, Capping Drug Costs for Seniors Act of 2021 H.R. 5260, Reduced Costs and Continued Cures Act H.R. 6973, Enhanced Access to Affordable Medicines Act of 2022 H.R. 7634, Protecting Health Care for All Patients Act of 2022 S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 S. 2317, Seniors Prescription Drug Relief Act Issues related to Medicare Part D coverage for drugs indicated to treat patients with chronic kidney disease; Quality Improvement Program (QIP) in the End Stage Renal Disease (ESRD) prospective payment system; CY 2022 Medicare End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and Quality Improvement Program (QIP) rule making; CY 2022 policy and technical issues changes to the Medicare Advantage Program and Medicare Prescription Drug Benefit Program; Centers for Medicare and Medicaid Innovation (CMMI) ESRD Treatment Choices (ETC) model; Implementation of expanded Medicare immunosuppressive drug coverage for kidney transplant patients; Implementation of Executive Order 13879, Advancing American Kidney Health; Telehealth flexibilities for nephrologists and kidney patients on dialysis.
AKEBIA THERAPEUTICS, INC. via AKEBIA THERAPEUTICS, INC.
2022 · second_quarter · Q2
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 1255/S. 377, The Living Donor Protection Act of 2021 H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 5376, Build Back Better Act, provisions relating to health care H.R. 5585, Advanced Research Project Agency Health Act H.R. 6000, Cures 2.0 Act S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 Implementation of Executive Order 13879, Advancing American Kidney Health.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 2934, Renal Anemia Innovation Support and Expansion (RAISE) Act S. 4011, Capping Drug Costs for Seniors Act of 2022 H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 4417, Capping Drug Costs for Seniors Act of 2021 H.R. 5260, Reduced Costs and Continued Cures Act H.R. 6973, Enhanced Access to Affordable Medicines Act of 2022 H.R. 7634, Protecting Health Care for All Patients Act of 2022 S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 S. 2317, Seniors Prescription Drug Relief Act Issues related to Medicare Part D coverage for drugs indicated to treat patients with chronic kidney disease; Quality Improvement Program (QIP) in the End Stage Renal Disease (ESRD) prospective payment system; CY 2022 Medicare End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and Quality Improvement Program (QIP) rule making; CY 2022 policy and technical issues changes to the Medicare Advantage Program and Medicare Prescription Drug Benefit Program; Centers for Medicare and Medicaid Innovation (CMMI) ESRD Treatment Choices (ETC) model; Implementation of expanded Medicare immunosuppressive drug coverage for kidney transplant patients; Implementation of Executive Order 13879, Advancing American Kidney Health; Telehealth flexibilities for nephrologists and kidney patients on dialysis.
AKEBIA THERAPEUTICS, INC. via AKEBIA THERAPEUTICS, INC.
2022 · first_quarter · Q1
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 2934, Renal Anemia Innovation Support and Expansion (RAISE) Act S. 4011, Capping Drug Costs for Seniors Act of 2022 H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 4417, Capping Drug Costs for Seniors Act of 2021 H.R. 5260, Reduced Costs and Continued Cures Act S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 S. 2317, Seniors Prescription Drug Relief Act Issues related to Medicare Part D coverage for drugs indicated to treat patients with chronic kidney disease; Quality Improvement Program (QIP) in the End Stage Renal Disease (ESRD) prospective payment system; CY 2022 Medicare End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and Quality Improvement Program (QIP) rule making; CY 2022 policy and technical issues changes to the Medicare Advantage Program and Medicare Prescription Drug Benefit Program; Centers for Medicare and Medicaid Innovation (CMMI) ESRD Treatment Choices (ETC) model; Implementation of expanded Medicare immunosuppressive drug coverage for kidney transplant patients; Implementation of Executive Order 13879, Advancing American Kidney Health; Telehealth flexibilities for nephrologists and kidney patients on dialysis.
AKEBIA THERAPEUTICS, INC. via AKEBIA THERAPEUTICS, INC.
2021 · fourth_quarter · Q4
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act; H.R. 1676, Jack Reynolds Memorial Medigap Extension Act; H.R. 1255/S. 377, The Living Donor Protection Act of 2021; H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act; H.R. 5376, Build Back Better Act, provisions relating to health care; H.R. 6000, Cures 2.0 Act; S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021; Implementation of Executive Order 13879, Advancing American Kidney Health.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 2934, Renal Anemia Innovation Support and Expansion (RAISE) Act H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 4417, Capping Drug Costs for Seniors Act of 2021 H.R. 5260, Reduced Costs and Continued Cures Act S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 S. 2317, Seniors Prescription Drug Relief Act Issues related to Medicare Part D coverage for drugs indicated to treat patients with chronic kidney disease; Quality Improvement Program (QIP) in the End Stage Renal Disease (ESRD) prospective payment system; CY 2022 Medicare End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and Quality Improvement Program (QIP) rule making; CY 2022 policy and technical issues changes to the Medicare Advantage Program and Medicare Prescription Drug Benefit Program; Centers for Medicare and Medicaid Innovation (CMMI) ESRD Treatment Choices (ETC) model; Implementation of expanded Medicare immunosuppressive drug coverage for kidney transplant patients; Implementation of Executive Order 13879, Advancing American Kidney Health; Telehealth flexibilities for nephrologists and kidney patients on dialysis.
AKEBIA THERAPEUTICS, INC. via AKEBIA THERAPEUTICS, INC.
2021 · third_quarter · Q3
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 2934, Renal Anemia Innovation Support and Expansion (RAISE) Act H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 4417, Capping Drug Costs for Seniors Act of 2021 H.R. 5260, Reduced Costs and Continued Cures Act S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 S. 2317, Seniors Prescription Drug Relief Act Issues related to Medicare Part D coverage for drugs indicated to treat patients with chronic kidney disease; Quality Improvement Program (QIP) in the End Stage Renal Disease (ESRD) prospective payment system; CY 2022 Medicare End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and Quality Improvement Program (QIP) rule making; CY 2022 policy and technical issues changes to the Medicare Advantage Program and Medicare Prescription Drug Benefit Program; Centers for Medicare and Medicaid Innovation (CMMI) ESRD Treatment Choices (ETC) model; Implementation of expanded Medicare immunosuppressive drug coverage for kidney transplant patients; Implementation of Executive Order 13879, Advancing American Kidney Health; Telehealth flexibilities for nephrologists and kidney patients on dialysis.
AKEBIA THERAPEUTICS, INC. via AKEBIA THERAPEUTICS, INC.
2021 · second_quarter · Q2
H.R. 1676, Jack Reynolds Memorial Medigap Extension Act; Issues related to Medicare Part D coverage for drugs indicated to treat patients with chronic kidney disease; H.R. 2934, Renal Anemia Innovation Support and Expansion (RAISE) Act H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act; S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021; CY 2022 Medicare End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and Quality Improvement Program (QIP) rule making; CY 2022 policy and technical issues changes to the Medicare Advantage Program and Medicare Prescription Drug Benefit Program; Centers for Medicare and Medicaid Innovation (CMMI) ESRD Treatment Choices (ETC) model; Implementation of expanded Medicare immunosuppressive drug coverage for kidney transplant patients; Implementation of Executive Order 13879, Advancing American Kidney Health; Telehealth flexibilities for nephrologists and kidney patients on dialysis.
H.R. 1676, Jack Reynolds Memorial Medigap Extension Act; H.R. 1255/S. 377, The Living Donor Protection Act of 2021; H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act; S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021; Direct distribution of COVID-19 vaccines to dialysis facilities by HHS; Implementation of Executive Order 13879, Advancing American Kidney Health.
AKEBIA THERAPEUTICS, INC. via AKEBIA THERAPEUTICS, INC.
2021 · first_quarter · Q1
H.R. 1676, Jack Reynolds Memorial Medigap Extension Act; H.R. 1255/S. 377, The Living Donor Protection Act of 2021; Direct distribution of COVID-19 vaccines to dialysis facilities by HHS; Implementation of Executive Order 13879, Advancing American Kidney Health.
H.R. 1676, Jack Reynolds Memorial Medigap Extension Act; Issues related to Medicare Part D coverage for drugs indicated to treat patients with chronic kidney disease; CY 2022 Medicare End Stage Renal Disease (ESRD) Prospective Payment System (PPS) and Quality Improvement Program (QIP) rule making; CY 2022 policy and technical issues changes to the Medicare Advantage Program and Medicare Prescription Drug Benefit Program; Centers for Medicare and Medicaid Innovation (CMMI) ESRD Treatment Choices (ETC) model; Implementation of expanded Medicare immunosuppressive drug coverage for kidney transplant patients; Implementation of Executive Order 13879, Advancing American Kidney Health; Telehealth flexibilities for nephrologists and kidney patients on dialysis.
AKEBIA THERAPEUTICS, INC. via AKEBIA THERAPEUTICS, INC.
2020 · fourth_quarter · Q4
Issues related to Medicare reimbursement for Part D drugs; Issues related to CY2021 End Stage Renal Disease (ERSD) Prospective Payment System; Medigap insurance access for ESRD beneficiaries; H.R. 133, Consolidated Appropriations Act of 2021 H.R. 3436, Seniors' Chronic Care Management Improvements Act of 2019; H.R. 3912/S. 1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019; CY2021 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescriptioon Drug Benefit Program, and Medicare Cost Plan Program rule; H.R. 5534/S. 3353, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2020 H.R. 8177, Renal Anemia Innovation Support and Expansion (RAISE) Act; H.R. 8181, Jack Reynold's Memory MediGap Expansion; Coronavirus Aid Relief, and Economic Security (CARES) Act (P.L. 116-146).
Issues related to Medicare reimbursement for Part D drugs; Issues related to CY2021 End Stage Renal Disease (ERSD) Prospective Payment System; Medigap insurance access for ESRD beneficiaries; H.R. 133, Consolidated Appropriations Act of 2021 H.R. 3436, Seniors' Chronic Care Management Improvements Act of 2019; H.R. 3912/S. 1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019; CY2021 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescriptioon Drug Benefit Program, and Medicare Cost Plan Program rule; H.R. 5534/S3353, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2020 H.R. 8177, Renal Anemia Innovation Support and Expansion (RAISE) Act; H.R. 8181, Jack Reynold's Memory MediGap Expansion; Coronavirus Aid Relief, and Economic Security (CARES) Act (P.L. 116-146).
AKEBIA THERAPEUTICS, INC. via AKEBIA THERAPEUTICS, INC.
2020 · third_quarter · Q3
Issues related to Medicare reimbursement for Part D drugs; Issues related to CY2021 End Stage Renal Disease (ERSD) Prospective Payment System; Medigap insurance access for ESRD beneficiaries; H.R. 3436, Seniors' Chronic Care Management Improvements Act of 2019; H.R. 3912/S. 1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019; CY2021 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescriptioon Drug Benefit Program, and Medicare Cost Plan Program rule; H.R. 8177, Renal Anemia Innovation Support and Expansion (RAISE) Act; H.R. 8181, Jack Reynold's Memory MediGap Expansion; Coronavirus Aid Relief, and Economic Security (CARES) Act (P.L. 116-146).
Issues related to Medicare reimbursement for Part D drugs; Issues related to CY2021 End Stage Renal Disease (ERSD) Prospective Payment System; Medigap insurance access for ESRD beneficiaries; H.R. 3436, Seniors' Chronic Care Management Improvements Act of 2019; H.R. 3912/S. 1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019; CY2021 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescriptioon Drug Benefit Program, and Medicare Cost Plan Program rule; H.R. 8177, Renal Anemia Innovation Support and Expansion (RAISE) Act; H.R. 8181, Jack Reynold's Memory MediGap Expansion; Coronavirus Aid Relief, and Economic Security (CARES) Act (P.L. 116-146).
AKEBIA THERAPEUTICS, INC. via AKEBIA THERAPEUTICS, INC.
2020 · second_quarter · Q2
Issues related to Medicare reimbursement for Part D drugs; Issues related to CY2021 End Stage Renal Disease (ERSD) Prospective Payment System; Medigap insurance access for ESRD beneficiaries; S. 1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019; H.R. 3436, Seniors' Chronic Care Management Improvements Act of 2019; H.R. 3912, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019; CY2021 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescriptioon Drug Benefit Program, and Medicare Cost Plan Program rule; H.R. 748, The Coronavirus Aid, Relief, and Economic Security (CARES) Act.
Issues related to Medicare reimbursement for Part D drugs; Issues related to CY2021 End Stage Renal Disease (ESRD) Prospective Payment System; Medigap insurance access for ESRD beneficiaries; S. 1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019; H.R. 3436, Senior's Chronic Care Management Improvement Act of 2019; H.R. 3912, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019; CY 2021 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Program, and Medicare Cost Plan Program rule; H.R. 748, The Coronovirus Aid, Relief, and Economic Security (CARES) Act
AKEBIA THERAPEUTICS, INC. via AKEBIA THERAPEUTICS, INC.
2020 · first_quarter · Q1
Issues related to Medicare reimbursement for Part D drugs; Issues related to CY2020 End Stage Renal Disease (ERSD) Prospective Payment System; Medigap insurance access for ESRD beneficiaries; S. 1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019; H.R. 3436, Seniors' Chronic Care Management Improvements Act of 2019; H.R> 3912, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019 Administrative action to provide relief for health care providers during the COVID-19 crisis.
Issues related to Medicare reimbursement for Part D drugs; Issues related to CY2020 End Stage Renal Disease (ERSD) Prospective Payment System; Medigap insurance access for ESRD beneficiaries; S. 1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019; H.R. 3436, Seniors' Chronic Care Management Improvements Act of 2019; H.R> 3912, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
AKEBIA THERAPEUTICS, INC. via AKEBIA THERAPEUTICS, INC.
2019 · fourth_quarter · Q4
Issues related to Medicare reimbursement for Part D drugs; Issues related to CY2020 End Stage Renal Disease (ERSD) Prospective Payment System; Medigap insurance access for ESRD beneficiaries; S. 1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019; H.R. 3436, Seniors' Chronic Care Management Improvements Act of 2019; H.R. 3912, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019
Issues related to Medicare reimbursement for Part D drugs; Issues related to CY2020 End Stage Renal Disease (ESRD) Prospective Payment System; Medigap insurance access for ESRD beneficiaries; S. 1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019;H.R. 3436, Senior's Chronic Care Management Improvement Act of 2019; H.R. 3912, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
AKEBIA THERAPEUTICS, INC. via AKEBIA THERAPEUTICS, INC.
2019 · third_quarter · Q3
Issues related to Medicare reimbursement for Part D drugs; Issues related to CY2020 End Stage Renal Disease (ERSD) Prospective Payment System; Medigap insurance access for ESRD beneficiaries; S. 1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019; H.R. 3436, Seniors' Chronic Care Management Improvements Act of 2019; H.R. 3912, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019
Issues related to Medicare reimbursement for Part D drugs; Issues related to CY2020 End Stage Renal Disease (ESRD) Prospective Payment System; Medigap insurance access for ESRD beneficiaries; S. 1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019;H.R. 3436, Senior's Chronic Care Management Improvement Act of 2019; H.R. 3912, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AKEBIA THERAPEUTICS, INC. via AKEBIA THERAPEUTICS, INC.
2019 · second_quarter · Q2
Issues related to Medicare reimbursement for Part D drugs; Issues related to CY2020 End Stage Renal Disease (ERSD) Prospective Payment System; Medigap insurance access for ESRD beneficiaries; S. 1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019; H.R. 3436, Seniors' Chronic Care Management Improvements Act of 2019
Issues related to Medicare reimbursement for Part D drugs; Issues related to CY2020 End Stage Renal Disease (ESRD) Prospective Payment System; Medigap insurance access for ESRD beneficiaries; S. 1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019;H.R. 3436, Senior's Chronic Care Management Improvement Act of 2019
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
AKEBIA THERAPEUTICS, INC. via AKEBIA THERAPEUTICS, INC.
2019 · first_quarter · Q1
Issues related to Medicare reimbursement for Part D drugs; Issues related to CY2020 End Stage Renal Disease (ERSD) Prospective Payment System; Medigap insurance access for ESRD beneficiaries
Issues related to Medicare reimbursement for Part D drugs; Issues related to CY2020 End Stage Renal Disease (ESRD) Prospective Payment System; Medigap insurance access for ESRD beneficiaries
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AKEBIA THERAPEUTICS, INC. via AKEBIA THERAPEUTICS, INC.
2018 · fourth_quarter · Q4
Proposed rule on CY 2019 ESRD Prospective Payment System (PPS) and Quality Improvement Program (QIP). Payment for new drugs and expansion of Transitional Drug Add-On Payment (TDAPA)in the ESRD PPS. Medicare Part D coverage for outpatient drugs, including patient coinsurance and manufacturer obligations in the coverage gap. Medicare Secondary Payer period for dialysis patients.
Implementation of P.L. 115-123, the Bipartisan Budget Act (BBA) of 2018.
H.R. 3976, "Access to Marketplace Insurance Act." H.R. 2644, "Chronic Kidney Disease Improvement in Research and Treatment Act of 2017." S. 1890, "Chronic Kidney Disease Improvement in Research and Treatment Act of 2017." Guaranteeing Medigap insurance for End Stage Renal Disease (ESRD) patients. Providing the ability of ESRD patients to enroll in Medicare Advantage (MA). KidneyX, HHS initiative to accelerate the development of drugs, devices and digital health tools for prevention, diagnosis and treatment of Chronic Kidney Disease (CKD). Withdrawal of interim final rule on charitable premium assistance payments.
AKEBIA THERAPEUTICS, INC. via AKEBIA THERAPEUTICS, INC.
2018 · third_quarter · Q3
Proposed rule on CY 2019 ESRD Prospective Payment System (PPS) and Quality Improvement Program (QIP). Payment for new drugs and expansion of Transitional Drug Add-On Payment (TDAPA)in the ESRD PPS. Medicare Part D coverage for outpatient drugs, including patient coinsurance and manufacturer obligations in the coverage gap. Medicare Secondary Payer period for dialysis patients.
H.R. 3976, "Access to Marketplace Insurance Act." H.R. 2644, "Chronic Kidney Disease Improvement in Research and Treatment Act of 2017." S. 1890, "Chronic Kidney Disease Improvement in Research and Treatment Act of 2017." Guaranteeing Medigap insurance for End Stage Renal Disease (ESRD) patients. Providing the ability of ESRD patients to enroll in Medicare Advantage (MA). KidneyX, HHS initiative to accelerate the development of drugs, devices and digital health tools for prevention, diagnosis and treatment of Chronic Kidney Disease (CKD). Withdrawal of interim final rule on charitable premium assistance payments.
AKEBIA THERAPEUTICS, INC. via AKEBIA THERAPEUTICS, INC.
2018 · third_quarter · RR
End Stage Renal Disease (ESRD) and kidney disease, generally; and issues specifically relating to ESRD drugs, innovation, and reimbursement (including Medicare coverage and reimbursement)
End Stage Renal Disease (ESRD) and kidney disease, generally; and issues specifically relating to ESRD drugs, innovation, and reimbursement (including Medicare coverage and reimbursement)
End Stage Renal Disease (ESRD) and kidney disease, generally; and issues specifically relating to ESRD drugs, innovation, and reimbursement (including Medicare coverage and reimbursement)
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Policy Development, SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Policy Development, SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), Office of Policy Development, SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 1255/S. 377, The Living Donor Protection Act of 2021 H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 5376, Build Back Better Act, provisions relating to health care H.R. 5585, Advanced Research Project Agency Health Act H.R. 6000, Cures 2.0 Act S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 Implementation of Executive Order 13879, Advancing American Kidney Health.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1676, Jack Reynolds Memorial Medigap Extension Act H.R. 1255/S. 377, The Living Donor Protection Act of 2021 H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act H.R. 5376, Build Back Better Act, provisions relating to health care H.R. 5585, Advanced Research Project Agency Health Act H.R. 6000, Cures 2.0 Act S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021 Implementation of Executive Order 13879, Advancing American Kidney Health.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
H.R. 1676, Jack Reynolds Memorial Medigap Extension Act; H.R. 1255/S. 377, The Living Donor Protection Act of 2021; H.R. 4065, The Chronic Kidney Disease Improvement in Research and Treatment Act; S. 1971, Chronic Kidney Disease Improvement in Research and Treatment Act of 2021; Implementation of Executive Order 13879, Advancing American Kidney Health.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Implementation of P.L. 115-123, the Bipartisan Budget Act (BBA) of 2018.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE